WO2019225707A1 - Differentiation inducer of myeloid stem cells, agent for improving epidermis, skin external agent, and method for improving epidermis - Google Patents

Differentiation inducer of myeloid stem cells, agent for improving epidermis, skin external agent, and method for improving epidermis Download PDF

Info

Publication number
WO2019225707A1
WO2019225707A1 PCT/JP2019/020506 JP2019020506W WO2019225707A1 WO 2019225707 A1 WO2019225707 A1 WO 2019225707A1 JP 2019020506 W JP2019020506 W JP 2019020506W WO 2019225707 A1 WO2019225707 A1 WO 2019225707A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
epidermis
stem cells
bone marrow
marrow stem
Prior art date
Application number
PCT/JP2019/020506
Other languages
French (fr)
Japanese (ja)
Inventor
勝規 久下
康二 福田
あゆみ 上野
由季 近藤
浩一 仲尾次
濱田 和彦
明人 前田
安史 金田
克人 玉井
Original Assignee
ピアス株式会社
国立大学法人大阪大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピアス株式会社, 国立大学法人大阪大学 filed Critical ピアス株式会社
Publication of WO2019225707A1 publication Critical patent/WO2019225707A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/58Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • the present invention relates to a differentiation inducer for bone marrow stem cells, an epidermis improving agent, an external preparation for skin, and an epidermis improving method.
  • ES cells embryonic stem cells
  • Somatic stem cells which are cells in a state, are known. Somatic stem cells are present in various tissues in the body. As somatic stem cells, for example, bone marrow stem cells existing in the bone marrow are known.
  • Bone marrow stem cells are attracting attention as being able to restore tissue function by differentiating into tissue cells in a tissue that has lost function. Specifically, bone marrow stem cells are attracted and accumulated in the bloodstream in inflamed or damaged tissues, and differentiate into the tissue cells under the influence of differentiation-inducing agents that induce differentiation. It is attracting attention as something to gain.
  • PDGF-BB as a platelet-derived growth factor (Platelet-DerivedrivGrowth Factor) is included, and bone marrow stem cells are differentiated into muscle tissue cells.
  • a differentiation-inducing agent to be obtained is known (Patent Document 1).
  • an object of the present invention is to provide a bone marrow stem cell differentiation inducer capable of inducing differentiation of bone marrow stem cells into epidermal cells.
  • Another object of the present invention is to provide an epidermis improving agent, an external preparation for skin, and a method for improving epidermis, which can improve epidermal function by attracting bone marrow stem cells to the epidermis to differentiate into epidermal cells.
  • the differentiation-inducing agent for bone marrow stem cells according to the present invention is characterized by containing a neem leaf extract and a black tea extract. It is preferable that said differentiation inducer further contains eggplant fruit extract.
  • the epidermis improving agent and external preparation for skin according to the present invention are characterized by containing an attractant for bone marrow stem cells, a neem leaf extract, and a black tea extract.
  • the above-mentioned epidermis improving agent and external preparation for skin preferably further contain eggplant fruit extract.
  • the method for improving the epidermis according to the present invention comprises attracting bone marrow stem cells to the epidermis by applying the above-mentioned epidermis improving agent or the above-mentioned external preparation for skin to the epidermis, and differentiating the attracted bone marrow stem cells into epidermal cells.
  • the graph showing the evaluation test result in connection with differentiation induction The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result in connection with differentiation induction. The graph showing the evaluation test result of the epidermis improvement effect in a human. The figure which showed the mode of the cell attraction test method typically.
  • the differentiation-inducing agent for bone marrow stem cells of the present embodiment includes a neem leaf extract and a black tea extract. According to the bone marrow stem cell differentiation inducer of this embodiment, bone marrow stem cells can be induced to differentiate into epidermal cells.
  • Bone marrow stem cells are one type of mesenchymal stem cells. Bone marrow stem cells are stem cells produced in the bone marrow. Bone marrow stem cells are also contained in blood and can be carried to each tissue in the body along the bloodstream.
  • the neem leaf extract is obtained by subjecting the leaves of neem belonging to the genus Azadiracta to the extraction process with an extraction solvent.
  • the neem leaf extract contains components extracted from neem leaf by the extraction solvent.
  • the scientific name of neem is Melia azadirachta L. (Meliceae) . Neem is called Neem in English.
  • the neem leaf extract can be obtained, for example, by subjecting heat-treated neem leaves to extraction with an extraction solvent.
  • the black tea extract is obtained by subjecting the leaves of standard varieties belonging to the camellia family Camellia (including varieties Assamcha) to extraction with an extraction solvent.
  • the black tea extract contains components extracted from the leaves of tea tree by the extraction solvent.
  • the scientific name of the standard variant, Chanoki is Thea sinensis Linne . Chanoki includes toucha and safflower.
  • the scientific name of Assamcha is Thea sinensis Linne var. Assamica Pierre (Theaceae) .
  • the black tea extract is an extract of Assamcha leaves.
  • the black tea extract is obtained by subjecting tea leaves (black tea) that has been completely fermented (oxidative fermentation process) to extraction with an extraction solvent.
  • tea leaves black tea
  • completely fermented black tea include Assam black tea, Darjeeling black tea, and Ceylon black tea.
  • the bone marrow stem cell differentiation inducer of this embodiment further includes an eggplant fruit extract.
  • the differentiation inducer further contains eggplant fruit extract, there is an advantage that differentiation of bone marrow stem cells into epidermal cells can be more fully induced.
  • the eggplant fruit extract is obtained by subjecting an eggplant ( Solanum melongena ) fruit belonging to the genus Solanum to an extraction solvent with an extraction solvent.
  • an eggplant Solanum melongena
  • Mizunas is preferable.
  • the scientific name of Miznas is Solanum melongena (Mizunasu) .
  • the above eggplant fruit extract can be obtained by subjecting eggplant fruit to extraction with an extraction solvent.
  • each extract described above can be in the state of an extract containing an extraction solvent or a diluting solvent, or in the form of a dried product from which the extraction solvent has been removed.
  • each extract can be in a state of, for example, a solution, a paste, a gel, or a powder.
  • the extraction solvent examples include water; aliphatic monohydric alcohols such as methanol, ethanol, propanol, and butanol (organic compounds having 1 to 4 carbon atoms and one OH group (including structural isomers)); glycerin, propylene Aliphatic polyhydric alcohols such as glycol and 1,3-butylene glycol (organic compounds having 1 to 5 carbon atoms and having a plurality of OH groups); ketones such as acetone; diethyl ether, dioxane, acetonitrile, ethyl acetate, etc.
  • aliphatic monohydric alcohols such as methanol, ethanol, propanol, and butanol (organic compounds having 1 to 4 carbon atoms and one OH group (including structural isomers)
  • glycerin propylene Aliphatic polyhydric alcohols such as glycol and 1,3-butylene glycol (organic compounds having 1 to 5 carbon atoms and having a pluralit
  • Esters aromatics such as xylene, benzene and toluene; and organic solvents such as halogenated alkyls such as chloroform.
  • These extraction solvents may be used alone or in combination of two or more.
  • the mixing ratio of the mixed extraction solvent is not particularly limited, and is appropriately adjusted.
  • a solvent containing an aliphatic polyhydric alcohol is preferable, an extraction solvent containing 50% by mass or more of an aliphatic polyhydric alcohol (1,3-butylene glycol) is more preferable, and 1,3 -A solvent containing 90% by mass or more of butylene glycol is more preferable.
  • an extraction solvent for the black tea extract a solvent containing an aliphatic monohydric alcohol is preferable, an extraction solvent containing an aliphatic monohydric alcohol (ethanol) at 50% by mass or more is more preferable, and a solvent containing ethanol at 90% by mass or more is preferable. Further preferred.
  • the extract extracted with the aliphatic monohydric alcohol may be dissolved with an aliphatic polyhydric alcohol such as 1,3-butylene glycol.
  • an extraction solvent for the eggplant fruit extract a mixed solvent containing water and an aliphatic polyhydric alcohol (for example, 1,3-butylene glycol) is preferable.
  • the mixing ratio of water and the aliphatic polyhydric alcohol (1,3-butylene glycol) is preferably 7: 3 (water: aliphatic polyhydric alcohol).
  • the extraction method is not particularly limited, and a conventionally known general extraction method can be employed.
  • the extraction site (leaves and fruits) of each plant can be used as it is or after drying as an extraction raw material.
  • the amount of extraction solvent is 5 to 15 times the mass of the extraction raw material (mass ratio)
  • the extraction temperature is 20 ° C. to 80 ° C.
  • the extraction time is 2 hours to 3 days.
  • purification treatment such as filtration, deodorization, and decolorization can be performed as necessary.
  • the mass ratio of neem leaf extract to black tea extract is preferably 1/1 or more and 23/1 or less in terms of dry matter. It is more preferably 2/1 or more and 5/1 or less, and further preferably 3/1 or more and 5/1 or less.
  • the mass ratio of the total amount of neem leaf extract and black tea extract (neem leaf extract and black tea extract / eggplant extract) to the mass of eggplant fruit extract is 1/1 or more and 7/1 or less. It is preferable that the ratio is 1/1 or more and 5/1 or less.
  • dry matter conversion is converting into the mass of the dry matter which removed the solvent contained in an extract from the extract.
  • the concentration of each of the extracts contained in the bone marrow stem cell differentiation inducer is not particularly limited.
  • the concentration of neem leaf extract is 0.0005% by mass or more and 0.075% by mass or less in terms of dry matter.
  • the concentration of the black tea extract is 0.00015% by mass or more and 0.03% by mass or less in terms of dry matter.
  • concentration of eggplant fruit extract is 0.0001 mass% or more and 0.015 mass% or less in conversion of a dry matter.
  • the differentiation-inducing agent for bone marrow stem cells of the present embodiment may contain water, ethanol, polyhydric alcohol, oil, surfactant, thickener, preservative, pH adjuster, etc. in addition to the above-mentioned extracts. Good.
  • the differentiation-inducing agent for bone marrow stem cells of the present embodiment may be in a liquid, gel-like, cream-like or solid state, for example.
  • the differentiation inducing agent for bone marrow stem cells of the present embodiment may be, for example, an external preparation for skin application or skin application.
  • the bone marrow stem cell differentiation inducer of the present embodiment may be used in applications such as cosmetics, pharmaceuticals, and quasi drugs.
  • each of the epidermis improving agent and the external preparation for skin of the present embodiment contains an attractant for bone marrow stem cells, the above neem leaf extract, and the above black tea extract. It is preferable that the epidermis improving agent and skin external preparation of this embodiment further contain said eggplant fruit extract.
  • the above-mentioned attractant for bone marrow stem cells is not particularly limited as long as it is applied to the epidermis and attracts bone marrow stem cells in the bloodstream to the epidermis.
  • concentration of the said attractant (total amount of compound amount and dry matter conversion amount) contained in an epidermis improving agent or a skin external preparation is not specifically limited, For example, it is 0.00001 mass% or more and 10 mass% or less.
  • the concentration of the neem leaf extract contained in the epidermis improving agent or the external preparation for skin is, for example, 0.0005 mass% or more and 0.075 mass% or less in terms of dry matter
  • the concentration of the tea extract is, for example, It is 0.00015% by mass or more and 0.03% by mass or less in terms of dry matter.
  • the above attractants include bodaiju extract, button pipi extract, coxnohagashi extract, asenyaku extract, pashanbe extract, cinnamtannin B1, pentagalloyl glucose, borkensiflavone, moreroflavone, kaempferitrin, quercetin-3 , 7-ziramnoside, procyanidin A2, procyanidin B1, deacetylcytochalasin C, a culture of Eupenicillium ludwigii , and at least one selected from the group consisting of a culture of Talaromyces trachyspermus Preferably there is.
  • the above body extract is obtained by subjecting a plant of the family Tiliaceae to extraction with an extraction solvent.
  • Plants of the family Tiliaceae include tree swordfish ( Tilia platyphyllos Scop. ), Tree swordfish ( Tilia.cordata Mill. ), Linden tree ( Tilia.europaea L. ), or other related plants.
  • the plant of the family Tiliaceae is preferably a coral mill ( Tilia.cordata Mill. ) In that it can attract bone marrow stem cells more reliably. That is, as the body extract, the body extract is preferable.
  • the extraction site of the lindenaceae plant is not particularly limited, and examples thereof include flowers, fruits, and bark.
  • the extracted site is preferably a flower (flower part) in that bone marrow stem cells can be attracted more reliably.
  • an extraction solvent for the above-mentioned Bodaige extract an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
  • the button pi extract is obtained by subjecting the root bark of a button family button ( Paeonia suffruticosa Andrews ) to extraction with an extraction solvent.
  • an extraction solvent for the button pi extract an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
  • the above-mentioned Kusunohagashi extract is obtained by subjecting Kusnohagashi wrinkles ( Mallotus philippinensis ) belonging to Euphorbiaceae to extraction treatment with an extraction solvent.
  • Kusnohagashi wrinkles Mallotus philippinensis
  • an extraction solvent for the above-mentioned Kusunohagashi extract, an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
  • the asenyaku extract is obtained by subjecting asenyaku ( Uncaria gambir ) to an extraction treatment with an extraction solvent.
  • asenyaku Uncaria gambir
  • the extraction site of Acacia yak there are no particular limitations on the extraction site of Acacia yak, and examples include leaves and branches.
  • the Acacia yak extract an extract obtained by subjecting both leaves and branches to extraction with an extraction solvent is preferable in that bone marrow stem cells can be attracted more reliably.
  • the extraction solvent for the asenyaku extract an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
  • the above-mentioned Pashanbe extract is obtained by subjecting one or more Pashanbheda belonging to the genus Himalaya Yukinoshita to an extraction treatment with an extraction solvent.
  • Bergenia ligulata (Wall.) Engl. Bergenia stracheyi (Hook. F. & Thoms.) Engl. Or Bergenia ciliata (Haw.) Sternb. Etc.
  • the extraction site of the pashambe is not particularly limited, but a rhizome is preferable in that bone marrow stem cells can be attracted more reliably.
  • an extraction solvent for the Pasambe extract an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
  • the cinnamtannin B1 is a compound having a molecular structure represented by the following formula (1).
  • the concentration of cinnamtannin B1 is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the pentagalloyl glucose is a compound having a molecular structure represented by the following formula (2).
  • the concentration of pentagalloyl glucose is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the above-mentioned Volkensiflavone is a compound having a molecular structure represented by the following formula (3).
  • the concentration of Borkensiflavone is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the above morelloflavone “Morelloflavone” is a compound having a molecular structure represented by the following formula (4).
  • the concentration of moreroflavone is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the kaempferitrin (or kaempferol-3,7-dirhamnoside) is a compound having a molecular structure represented by the following formula (5).
  • the concentration of kaempferitrin is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the quercetin-3,7-dirhamnoside is a compound having a molecular structure represented by the following formula (6).
  • the concentration of quercetin-3,7-dirhamnoside is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the procyanidin A2 is a compound having a molecular structure represented by the following formula (7).
  • the concentration of procyanidin A2 is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the procyanidin B1 is a compound having a molecular structure represented by the following formula (8).
  • the concentration of procyanidin B1 is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the deacetylcytochalasin C is a compound having a molecular structure represented by the following formula (9).
  • the concentration of deacetylcytochalasin C is not particularly limited, and is, for example, 0.001 to 10% by mass.
  • the deacetylcytochalasin C is included in, for example, a product generated by culturing a black rot fungus ( Metarhizium anisopliae ) classified as a baby fungus microorganism.
  • the culture of the above-mentioned Eupenicillium ludwigii is included in the product produced by culturing Eupenicillium ludwigii classified as, for example, an aspergillus fungus microorganism ( Eupenicillium ludwigii ).
  • the culture of the above-mentioned Talaromyces trachyspermus ( Talaromyces trachyspermus ) is included in, for example, a product generated by culturing Talaromyces trachyspermus classified as an irregular fungus microorganism.
  • bone marrow stem cells can be attracted to the epidermis and differentiated into epidermal cells, and the epidermal function can be improved.
  • the epidermis has a stratum corneum layer, a granule layer, a spiny layer, and a basal layer in order from the outermost side, and epidermal cells existing in the basal layer are pushed up by metabolism to form cells of each layer.
  • the induced bone marrow stem cells can differentiate into basal layer epidermal cells.
  • the epidermis improving agent or external preparation for skin of this embodiment further includes water, ethanol, polyhydric alcohol, oil, surfactant, thickener, preservative, pH adjuster, and the like, as with the differentiation inducer described above. May be included.
  • the skin-improving agent of the present embodiment may be in a liquid, gel-like, cream-like, or solid state, for example.
  • the epidermis improving agent and external preparation for skin of this embodiment may be used, for example, for skin application or skin application.
  • the epidermis improving agent and external preparation for skin of this embodiment may be used in applications such as cosmetics, pharmaceuticals, and quasi drugs.
  • the epidermis improving agent and skin external preparation of this embodiment are used like the epidermis improving method mentioned later, for example.
  • the epidermal improvement method of this embodiment comprises attracting bone marrow stem cells to the epidermis by applying the above-mentioned epidermis improving agent or the above-mentioned external preparation for skin to the epidermis and differentiating the bone marrow stem cells into epidermal cells.
  • the epidermal function is worsened by a decrease in the number of cells constituting the epidermis and the disruption of the cell arrangement, as the epidermal stem cells that form the epidermal cells decrease with age. By increasing the number of epidermal stem cells in the epidermis, the once deteriorated epidermal function can be recovered.
  • the epidermis function can be recovered by attracting bone marrow stem cells to the epidermis by the epidermis improving agent or the above-mentioned external preparation for skin, and differentiating the bone marrow stem cells into epidermal cells in the epidermis.
  • the part of the epidermis to which the above-mentioned epidermis improving agent or external preparation for skin is applied is not particularly limited, and is, for example, the stratum corneum, granule layer, spiny layer, or basal layer. Such a portion of the epidermis may be a healthy part or a wound part.
  • bone marrow stem cells can be attracted to the epidermis by the above-mentioned epidermis improving agent or the skin external preparation attractant.
  • epidermis improving agent external preparation for skin
  • bone marrow stem cells in the blood can be attracted to the epidermal tissue.
  • the above-described method for improving the epidermis can be performed in situ on animals other than humans. In humans, it can be carried out non-therapeutically for the cosmetic purpose of improving the epidermal function. Beauty purposes include, for example, the purpose of improving skin firmness, the purpose of suppressing skin wrinkles, the purpose of suppressing skin drying, the purpose of suppressing skin dullness, the purpose of removing skin spots, or The purpose is to lighten the skin.
  • composition of differentiation-inducing agent, epidermis-improving agent, external preparation for skin and method for improving epidermis are as exemplified above, but the present invention is not limited to the above-exemplified embodiment. .
  • adopted in a general differentiation-inducing agent, an epidermis improving agent, an external preparation for skin, and an epidermis improving method can be employ
  • neem leaf extract The product name “Neem Leaf Liquid B” (manufactured by Ichimaru Falcos) was used as the neem leaf extract.
  • the method for producing such neem leaf extract is as follows. Extraction of neem leaf ( Melia azadirachta L. (Meliceae) ) after heat treatment, followed by extraction using 1,3-butylene glycol as an extraction solvent, followed by filtration It was a thing. The neem leaf extract was found to contain 1.1% by mass of dry matter when calculated from the remaining amount of evaporation after 5 mL of neem leaf extract was evaporated to dryness at 105 ° C. for 6 hours on a water bath ( Solid content concentration conversion).
  • Black tea extract The product name “Tea Liquid” (manufactured by Ichimaru Falcos) was used as the tea extract.
  • the manufacturing method of such a black tea extract is as follows. Assamcha ( Thea sinensis L. var. Assamica Pierre (Theaceae) ) leaves were extracted using ethanol as an extraction solvent, frozen, and filtered to obtain a filtrate. 1,3-butylene glycol was added to this filtrate and the resultant was filtered to obtain a black tea extract (Assam black tea extract). As calculated from the remaining amount of evaporation after 10 mL of black tea extract was evaporated to dryness at 105 ° C. for 6 hours on a water bath, the black tea extract contained 2.4% by mass of the dried product (solid content) Concentration conversion).
  • [Eggplant fruit extract] A commercially available eggplant fruit extract was used.
  • Test Example 1 The above neem leaf extract and the above black tea extract were mixed and diluted such that the total amount of the extract in terms of dry matter was 0.01% by mass (the value after rounding off), and Test Example 1 Samples were prepared.
  • a differentiation induction medium culture supernatant obtained by culturing epidermal cells for a long period of time
  • the mass ratio of the neem leaf extract to the black tea extract was 1/1 after rounding off.
  • Test Example 2 The above neem leaf extract and the above black tea extract were mixed and diluted such that the total amount of the extract in terms of dry matter was 0.01% by mass (number after rounding off), and Test Example 2 Samples were prepared.
  • a differentiation induction medium culture supernatant obtained by culturing epidermal cells for a long period of time
  • the mass ratio of neem leaf extract to black tea extract was 2/1 after rounding off.
  • Test Example 3 The above neem leaf extract and the above black tea extract were mixed and diluted so that the total amount of the extract in terms of dry matter was 0.01% by mass (number after rounding off), and Test Example 3 Samples were prepared.
  • a differentiation induction medium culture supernatant obtained by culturing epidermal cells for a long period of time
  • the mass ratio of the neem leaf extract to the black tea extract was 3/1 after rounding off.
  • Test Example 4 The above neem leaf extract and the above black tea extract were mixed and diluted so that the total amount of the extract in terms of dry matter was 0.01% by mass (number after rounding off), and Test Example 4 Samples were prepared.
  • a differentiation induction medium culture supernatant obtained by culturing epidermal cells for a long period of time
  • the mass ratio of neem leaf extract to black tea extract was 5/1 after rounding off.
  • Test Example 5 The above neem leaf extract and the above black tea extract were mixed and diluted so that the total amount of the extract in terms of dry matter was 0.01% by mass (number after rounding off), and Test Example 5 Samples were prepared.
  • a differentiation induction medium culture supernatant obtained by culturing epidermal cells for a long period of time
  • the mass ratio of neem leaf extract to black tea extract was 23/1 as a value after rounding off.
  • the neem leaf extract was diluted so that the amount of the neem leaf extract in terms of dry matter was 0.006% by mass and 0.011% by mass, respectively. Samples were prepared. As a dilution solvent, a differentiation induction medium (culture supernatant obtained by culturing epidermal cells for a long period of time) that induces differentiation of bone marrow stem cells into epidermal cells was used.
  • a differentiation induction medium culture supernatant obtained by culturing epidermal cells for a long period of time
  • the above black tea extract was diluted so that the dry tea equivalents of the black tea extract were 0.0002 mass%, 0.0024 mass%, and 0.0036 mass%, respectively. Five samples were prepared.
  • a differentiation induction medium culture supernatant obtained by culturing epidermal cells for a long period of time
  • differentiation of bone marrow stem cells into epidermal cells was used.
  • Bone marrow stem cells were seeded at 6,000 cells / well in a 96-well plate and cultured for 3 days. Separately, epidermal cells were seeded in a petri dish having a diameter of 10 cm, and when 90% confluent was reached, the medium was replaced with a new medium, and the supernatant culture solution was collected after 24 hours of culture. The solution obtained by centrifuging and filtering the collected supernatant culture solution was used as a differentiation induction medium (differentiation induction medium for inducing differentiation of bone marrow stem cells into epidermal cells).
  • differentiation induction medium differentiate induction medium for inducing differentiation of bone marrow stem cells into epidermal cells.
  • eggplant fruit extract was added to epidermal cells, the supernatant was collected after 24 hours of culture, and the solution obtained by centrifugation and filtration was used as a differentiation-inducing medium.
  • neem leaf extract and black tea extract were diluted using the prepared differentiation induction medium and added to cultured bone marrow stem cells, and then differentiation induction culture was performed for 9 to 10 days. After culturing, the degree of differentiation was evaluated by immune cell staining. Differentiation-induced bone marrow stem cells (MSC) were fixed with 4% paraformaldehyde (manufactured by WAKO), and then washed three times with PBS ( ⁇ ).
  • keratin 14 (K14) antibody and keratin 5 (K5) antibody expressed only in epidermal cells were used.
  • the degree of staining was evaluated by using a numerical value of the stained image (Dens level sum ⁇ Area) / Hoches) using an In cell analyzer device (GE Healthcare).
  • the evaluation test results relating to differentiation induction using Test Examples 1 to 5 are shown in FIG.
  • the evaluation test results in Reference Examples 1 and 2 are shown in FIGS. 2A and 2B.
  • the evaluation test results in Reference Examples 3 to 5 are shown in FIGS. 3A and 3B.
  • the evaluation test results using the eggplant fruit extract alone are shown in FIGS. 4A and 4B.
  • the evaluation test results of Test Examples 3 and 6 to 8 are shown in FIG.
  • bone marrow stem cells could be differentiated into epidermal cells by using a bone marrow stem cell differentiation inducer containing neem leaf extract and black tea extract.
  • a bone marrow stem cell attractant was prepared as follows. Using the prepared attractant, an in vitro cell attraction test was performed.
  • Attractant 1 A Bodaiju extract of Attractant 1 (Fuyubodaiju extract) was prepared. Specifically, 1L of a 50% ethanol aqueous solution is added to 100g of dried and finely crushed flowers of Tilia.cordata Mill , followed by extraction at room temperature (20 ° C) for 3 days, followed by filtration. went. Then, a dried product was obtained from the filtered solution by drying under reduced pressure, and this dried product was diluted with 1,3-butylene glycol to prepare a jujube extract. When calculated from the amount of the dry substance after the extraction solvent was removed by drying under reduced pressure, this body extract contained 0.45% by mass of the dried product.
  • buttons pea extract of attractant 2 were prepared.
  • 1L of 50 vol% ethanol aqueous solution was added to 100g of dried root bark of a button ( Paeonia suffruticosa Andrews ), followed by extraction at room temperature (20 ° C) for 3 days, followed by filtration. It was.
  • a dried product was obtained from the filtered solution by drying under reduced pressure, and the dried product was diluted with 1,3-butylene glycol to prepare a button pi extract.
  • This button pi extract when calculated from the amount of dry substance after removal of the extraction solvent by drying under reduced pressure, contained 0.90% by mass of the dried product.
  • a Kusunohagashi extract of attractant 3 was prepared. For details, add 2L of 50% ethanol aqueous solution to 200g of dried and finely crushed bark of Kusonohagashi ( Mallotus philippinensis Mueller-Argoviensis ), and perform extraction for 2 days while maintaining 60-80 ° C. went. Then, a dried product was obtained from the filtered liquid by drying under reduced pressure, and this dried product was diluted with 1,3-butylene glycol to prepare a Kusunohagashi extract. This Kusunohagashi extract contained 0.20% by mass of the dried product, as calculated from the amount of dry substance after the extraction solvent was removed by drying under reduced pressure.
  • Attractant 4" An asenyaku extract of attractant 4 was prepared. Specifically, 2 L of a 50% ethanol aqueous solution was added to 100 g of dried and finely crushed leaves and young branches of Acacia yam ( Uncaria gambir Roxburgh ), and the extraction operation was performed for 3 hours while maintaining 50 to 70 ° C. with stirring. Filtration was performed. A dried product was obtained from the filtered solution by drying under reduced pressure, and the dried product was diluted with 1,3-butylene glycol to prepare an asenyaku extract. This asenyaku extract was found to contain 4.10% by mass of the dried product when calculated from the amount of dry substance after the extraction solvent was removed by drying under reduced pressure.
  • a pashambe extract of attractant 5 was prepared. Specifically, 3 kg of a 50 vol% ethanol aqueous solution was added to 200 g of dried and finely crushed rhizomes of Pashambe ( Bergenia ligulata (Wall.) Engl. ), And extraction was performed at 50 ° C. for 8 hours while stirring. The crude extract was cooled, filtered, concentrated, and passed through a column packed with a synthetic adsorbent (trade name “Diaion HP-20” manufactured by Mitsubishi Chemical Corporation). After washing with water, the eluate eluted with a 30% by volume ethanol aqueous solution was dried under reduced pressure and redissolved in 1,3-butylene glycol to prepare a Pashambe extract. When calculated from the amount of dry substance after the extraction solvent was removed by drying under reduced pressure, this Pashambe extract contained 0.50% by mass of the dried product.
  • "Attractant 10” As the attractant 10 commercially available kaempferitrin was used.
  • “Attractant 11” As the attractant 11 commercially available quercetin-3,7-dirhamnoside was used.
  • “Attractant 12” As the attractant 12 commercially available procyanidin A2 was used.
  • Attractant 14 As shown below, an attractant containing deacetylcytochalasin C was prepared. That is, black rot fungus ( Metarhizium anisopliae ) was cultured, and a crude culture containing the cultured medium and cells was obtained. A culture extract was prepared by subjecting this crude culture to an extraction treatment. Details will be described below. First, in order to perform pre-culture of Metarhizium anisopliae , inoculum extracted from the glycerol stock was cultured according to the following culture conditions.
  • Pre-culture conditions Temperature 28 ° C., 40 days
  • Pre-culture medium composition LCA agar medium shown below 1 g glucose KH 2 PO 4 1g MgSO 4 ⁇ 7H 2 O 0.2g KCl 0.2g NaNO 3 2g
  • a main culture medium having the following composition is prepared in a 50 mL capacity centrifuge tube, and 1 mL of the above suspension is added to the main culture centrifuge tube. Main culture was performed.
  • Main culture conditions Temperature 28 ° C., 2 weeks ⁇
  • Main culture medium composition Solid medium shown below Vegetable juice 10 mL (Product name “V8 Juice” manufactured by Campbell Soup Company) Oatmeal 3g (Snow Brand Milk Products (Quaker))
  • An 80 vol% acetone aqueous solution as an extraction solvent was added to the centrifuge tube after the main culture, and the crude culture was extracted with the extraction solvent. Specifically, after adding the extraction solvent to the centrifuge tube, the centrifuge tube was vigorously shaken up and down to stir the contents, and allowed to stand at room temperature for 30 minutes. Thereafter, the centrifuge tube was centrifuged at 3500 rpm and 23 ° C.
  • the supernatant was allowed to stand for about 15 hours in a draft to evaporate the extraction solvent and concentrated, and then stored at ⁇ 20 ° C. until the concentrated supernatant reached about 10 mL.
  • the stored supernatant was placed in a microtube, and a precipitate and a sample solution other than the precipitate were obtained by centrifugation at 13,000 rpm. 225.6 ⁇ L of the sample solution (corresponding to 200 ⁇ L of main culture broth) was dried to dryness with a centrifugal evaporator and stored at ⁇ 20 ° C.
  • the dried sample is dissolved in 100 ⁇ L of 80% by volume methanol aqueous solution and suspended for 30 minutes using a vortex mixer, and then the supernatant is obtained by centrifugation at 13,500 rpm, 4 ° C. for 5 minutes, followed by culture extraction A product was prepared and an attractant was produced.
  • the attractant contained 15% by mass of a dried product as calculated from the amount of dry substance after removing the solvent. It was confirmed by nuclear magnetic resonance (NMR) and mass spectrometry (MS) that the attractant 14 produced as described above contained deacetylcytochalasin C.
  • Attractant 15 (culture of Eupenicillium ludwigii ) By culturing Eupenicillium ludwigii , a crude culture containing the cultured medium and cells was obtained. The crude culture was subjected to an extraction treatment to obtain a culture extract, and the attractant 15 was produced. Details thereof will be described below. First, the microbial cells taken out from the glycerol stock were planted in an inclined medium (malt extract agar medium (MA medium)) and pre-cultured for 1 week.
  • an inclined medium malt extract agar medium (MA medium)
  • the cells after pre-culture are removed with a platinum loop and suspended in 5 mL of sterile physiological saline, and then the entire suspension is put into a 150 mL polypropylene flask containing a medium having the following composition. Inoculated and statically cultured (25 ° C., 12 days).
  • Attractant 16 (culture of Talaromyces trachyspermus ) The attractant 16 was produced in the same manner as the attractant 15 except that Talaromyces trachyspermus was used instead of Eupenicillium ludwigii . The attractant contained 2% by mass of a dried product.
  • FIG. 7 schematically shows the state of the test method.
  • the concentration of the attractant is a predetermined concentration (1%, 0.1%, etc.) was prepared as a test sample.
  • DMEM Dulbecco's modified Eagle medium
  • FBS
  • P / S
  • a positive control sample a DMEM solution having a concentration of 20 ng / mL PDGF-BB (platelet-derived growth factor PEPRO TECH) was prepared.
  • mouse bone marrow stem cells (hereinafter also referred to as mMSC) are cultured and collected to confluence, suspended in 10% FBS / DMEM “P / S ( ⁇ )” to 1 ⁇ 10 7 cells / ml, and cell suspension A liquid was prepared.
  • FBS represents 10% fetal bovine serum
  • P / S represents 100 unit penicillin and 0.1 mg / mL streptomycin.
  • the symbol (-) indicates that no blending is performed.
  • a Boyden chamber B manufactured by Neuro Probe having a plurality of independent wells, in which the well is partitioned into an upper well P and a lower well Q by a membrane M as shown in FIG. Prepared.
  • each test sample was set so that a negative control sample and a positive control sample could be tested in the same Boyden chamber B, and 28 ⁇ L of each sample was applied to each lower well of the chamber B.
  • the membrane M of Boyden chamber B the trade name “Polycarbonate Membranes” (pore size 8 ⁇ m, manufactured by Neuro Probe) was used.
  • 50 ⁇ L of the cell suspension was seeded in each upper well P, and cultured for 4 hours under conditions of 37 ° C. and 5% CO 2 (see (b) in FIG. 7). After culturing for 4 hours, as shown in FIG.
  • the unmigrated mMSC was removed with the attached filter wiper R, and only the mMSC that had moved to the lower side of the membrane M was subjected to Diff-Quick staining (Sysmex kit). Used). Then, the stained image is digitized and loaded into a computer, and the image is converted to a white portion of the blue-stained portion so that the image is binarized into black and white. The measurement was performed using the function of editing software (trade name “Photoshop”). The mMSC attracting activity of each attractant was evaluated by comparing the brightness in the negative and positive control samples with the brightness in each test sample.
  • the results (brightness) of the cell attraction test are shown in Table 1. Of the results obtained using the sample in which the attractant was diluted to a predetermined concentration such as 1% concentration or 0.1% concentration, the result of the highest luminance is shown. Moreover, the result of a positive control and a negative control when the test is performed simultaneously is also shown. As can be seen from Table 1, each of the above attractants can attract bone marrow stem cells.
  • the differentiation-inducing agent of the present invention is suitable for the purpose of, for example, attracting bone marrow stem cells circulating in the body in the bloodstream to the epidermis tissue and differentiating the induced bone marrow stem cells into epidermal cells in the epidermis tissue.
  • the epidermis improving agent, external preparation for skin, and epidermal improvement method of the present invention, as described above, induces bone marrow stem cells to epidermal tissue, and further differentiates the induced bone marrow stem cells into epidermal cells to improve epidermal function. It is preferably used for the purpose.
  • the epidermis improving agent and the external preparation for skin of the present invention are applied to the epidermis to attract bone marrow stem cells to the epidermis, and the induced bone marrow stem cells are differentiated into epidermal cells to improve the appearance of the skin. And is preferably used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided is a differentiation inducer of myeloid stem cells, said agent comprising a neem leaf extract and a black tea extract. Also provided are an agent for improving epidermis and a skin external agent both further comprising an inducer of myeloid stem cells. The aforesaid differentiation inducer, agent for improving epidermis and skin external agent may further comprise an eggplant extract.

Description

骨髄幹細胞の分化誘導剤、表皮改善剤、皮膚外用剤、及び、表皮改善方法Bone marrow stem cell differentiation inducer, epidermis improving agent, skin external preparation, and epidermis improving method 関連出願の相互参照Cross-reference of related applications
 本願は、日本国特願2018―099943号の優先権を主張し、該出願が引用によって本願明細書の記載に組み込まれる。 This application claims the priority of Japanese Patent Application No. 2018-099443, which is incorporated herein by reference.
 本発明は、骨髄幹細胞の分化誘導剤、表皮改善剤、皮膚外用剤、及び、表皮改善方法に関する。 The present invention relates to a differentiation inducer for bone marrow stem cells, an epidermis improving agent, an external preparation for skin, and an epidermis improving method.
 未だ分化しておらず様々な組織細胞へと分化しうる幹細胞としては、受精卵が分化していない状態の細胞である胚性幹細胞(ES細胞)、分化した組織に含まれ未だ分化していない状態の細胞である体性幹細胞などが知られている。
 体性幹細胞は、体内の各種組織に存在するものであり、体性幹細胞としては、例えば、骨髄に存在する骨髄幹細胞が知られている。
Stem cells that have not yet differentiated and can differentiate into various tissue cells include embryonic stem cells (ES cells), which are cells in a state where fertilized eggs are not differentiated, and are not differentiated yet contained in differentiated tissues. Somatic stem cells, which are cells in a state, are known.
Somatic stem cells are present in various tissues in the body. As somatic stem cells, for example, bone marrow stem cells existing in the bone marrow are known.
 骨髄幹細胞は、機能が失われた組織においてその組織細胞に分化することによって組織の機能を回復させ得るものとして注目されている。具体的には、骨髄幹細胞は、炎症のある組織又は損傷を受けた組織へ血流にのって誘引されて集積し、分化を誘導する分化誘導剤の影響を受けてその組織細胞へ分化し得るものとして注目されている。 Bone marrow stem cells are attracting attention as being able to restore tissue function by differentiating into tissue cells in a tissue that has lost function. Specifically, bone marrow stem cells are attracted and accumulated in the bloodstream in inflamed or damaged tissues, and differentiate into the tissue cells under the influence of differentiation-inducing agents that induce differentiation. It is attracting attention as something to gain.
 ところで、従来、骨髄幹細胞を特定の組織細胞に分化させ得る分化誘導剤としては、例えば、血小板由来成長因子(Platelet-Derived Growth Factor)としてのPDGF-BBを含み骨髄幹細胞を筋肉組織細胞に分化させ得る分化誘導剤が知られている(特許文献1)。 By the way, conventionally, as a differentiation-inducing agent capable of differentiating bone marrow stem cells into specific tissue cells, for example, PDGF-BB as a platelet-derived growth factor (Platelet-DerivedrivGrowth Factor) is included, and bone marrow stem cells are differentiated into muscle tissue cells. A differentiation-inducing agent to be obtained is known (Patent Document 1).
国際公開第2005/063967号公報International Publication No. 2005/063967
 しかしながら、特許文献1に記載の分化誘導剤は、骨髄幹細胞を筋肉組織細胞へ分化誘導できるものの、例えば、骨髄幹細胞を表皮細胞へ分化誘導する性能を有しないという問題がある。 However, although the differentiation inducer described in Patent Document 1 can induce differentiation of bone marrow stem cells into muscle tissue cells, there is a problem that it does not have the ability to induce differentiation of bone marrow stem cells into epidermal cells, for example.
 本発明は、上記の問題点等に鑑み、骨髄幹細胞を表皮細胞へ分化誘導できる骨髄幹細胞の分化誘導剤を提供することを課題とする。
 また、本発明は、骨髄幹細胞を表皮に誘引して表皮細胞に分化させることによって表皮機能を改善できる表皮改善剤、皮膚外用剤、及び、表皮改善方法を提供することを課題とする。
In view of the above-mentioned problems and the like, an object of the present invention is to provide a bone marrow stem cell differentiation inducer capable of inducing differentiation of bone marrow stem cells into epidermal cells.
Another object of the present invention is to provide an epidermis improving agent, an external preparation for skin, and a method for improving epidermis, which can improve epidermal function by attracting bone marrow stem cells to the epidermis to differentiate into epidermal cells.
 本発明に係る骨髄幹細胞の分化誘導剤は、ニーム葉抽出物と紅茶抽出物とを含むことを特徴とする。上記の分化誘導剤は、ナス果実抽出物をさらに含むことが好ましい。 The differentiation-inducing agent for bone marrow stem cells according to the present invention is characterized by containing a neem leaf extract and a black tea extract. It is preferable that said differentiation inducer further contains eggplant fruit extract.
 本発明に係る表皮改善剤及び皮膚外用剤は、骨髄幹細胞の誘引剤と、ニーム葉抽出物と、紅茶抽出物とを含むことを特徴とする。上記の表皮改善剤及び皮膚外用剤は、ナス果実抽出物をさらに含むことが好ましい。 The epidermis improving agent and external preparation for skin according to the present invention are characterized by containing an attractant for bone marrow stem cells, a neem leaf extract, and a black tea extract. The above-mentioned epidermis improving agent and external preparation for skin preferably further contain eggplant fruit extract.
 本発明に係る表皮改善方法は、上記の表皮改善剤、又は、上記の皮膚外用剤を表皮に塗布することによって、骨髄幹細胞を表皮に誘引し、誘引した骨髄幹細胞を表皮細胞へ分化させることを備える。 The method for improving the epidermis according to the present invention comprises attracting bone marrow stem cells to the epidermis by applying the above-mentioned epidermis improving agent or the above-mentioned external preparation for skin to the epidermis, and differentiating the attracted bone marrow stem cells into epidermal cells. Prepare.
分化誘導に関わる評価試験結果を表すグラフ。The graph showing the evaluation test result in connection with differentiation induction. 分化誘導に関わる評価試験結果を表すグラフ。The graph showing the evaluation test result in connection with differentiation induction. 分化誘導に関わる評価試験結果を表すグラフ。The graph showing the evaluation test result in connection with differentiation induction. 分化誘導に関わる評価試験結果を表すグラフ。The graph showing the evaluation test result in connection with differentiation induction. 分化誘導に関わる評価試験結果を表すグラフ。The graph showing the evaluation test result in connection with differentiation induction. 分化誘導に関わる評価試験結果を表すグラフ。The graph showing the evaluation test result in connection with differentiation induction. 分化誘導に関わる評価試験結果を表すグラフ。The graph showing the evaluation test result in connection with differentiation induction. 分化誘導に関わる評価試験結果を表すグラフ。The graph showing the evaluation test result in connection with differentiation induction. ヒトにおける表皮改善作用の評価試験結果を表すグラフ。The graph showing the evaluation test result of the epidermis improvement effect in a human. 細胞誘引試験方法の様子を模式的に示した図。The figure which showed the mode of the cell attraction test method typically.
 以下に、本発明の骨髄幹細胞の分化誘導剤の実施形態について説明する。 Hereinafter, embodiments of the differentiation inducer for bone marrow stem cells of the present invention will be described.
 本実施形態の骨髄幹細胞の分化誘導剤は、ニーム葉抽出物と紅茶抽出物とを含むものである。本実施形態の骨髄幹細胞の分化誘導剤によれば、骨髄幹細胞を表皮細胞へ分化誘導できる。 The differentiation-inducing agent for bone marrow stem cells of the present embodiment includes a neem leaf extract and a black tea extract. According to the bone marrow stem cell differentiation inducer of this embodiment, bone marrow stem cells can be induced to differentiate into epidermal cells.
 骨髄幹細胞は、間葉系幹細胞の1種である。骨髄幹細胞は、骨髄で作り出される幹細胞である。骨髄幹細胞は、血液中にも含まれ、血流にのって体内の各組織へ運ばれ得るものである。 Bone marrow stem cells are one type of mesenchymal stem cells. Bone marrow stem cells are stem cells produced in the bone marrow. Bone marrow stem cells are also contained in blood and can be carried to each tissue in the body along the bloodstream.
 上記ニーム葉抽出物は、センダン科アザディラクタ属に属するインドセンダンの葉を抽出溶媒で抽出処理することによって得られるものである。換言すると、ニーム葉抽出物は、抽出溶媒によってインドセンダンの葉から抽出された成分を含む。インドセンダンの学名は、Melia azadirachta L. (Meliceae)である。インドセンダンは、英語でNeem(ニーム)と称される。 The neem leaf extract is obtained by subjecting the leaves of neem belonging to the genus Azadiracta to the extraction process with an extraction solvent. In other words, the neem leaf extract contains components extracted from neem leaf by the extraction solvent. The scientific name of neem is Melia azadirachta L. (Meliceae) . Neem is called Neem in English.
 上記ニーム葉抽出物は、例えば、加熱処理したインドセンダンの葉に対して、抽出溶媒で抽出処理を施すことによって得られる。 The neem leaf extract can be obtained, for example, by subjecting heat-treated neem leaves to extraction with an extraction solvent.
 上記紅茶抽出物は、ツバキ科ツバキ属に属する基準変種のチャノキ(変種のアッサムチャを含む)の葉に対して抽出溶媒で抽出処理を施すことによって得られるものである。換言すると、紅茶抽出物は、抽出溶媒によってチャノキの葉から抽出された成分を含む。基準変種のチャノキの学名は、Thea sinensis Linne である。チャノキには、トウチャやベニバナチャが含まれる。また、アッサムチャの学名は、Thea sinensis Linne var. assamica Pierre (Theaceae)である。本実施形態では、紅茶抽出物は、アッサムチャの葉の抽出物である。 The black tea extract is obtained by subjecting the leaves of standard varieties belonging to the camellia family Camellia (including varieties Assamcha) to extraction with an extraction solvent. In other words, the black tea extract contains components extracted from the leaves of tea tree by the extraction solvent. The scientific name of the standard variant, Chanoki , is Thea sinensis Linne . Chanoki includes toucha and safflower. The scientific name of Assamcha is Thea sinensis Linne var. Assamica Pierre (Theaceae) . In this embodiment, the black tea extract is an extract of Assamcha leaves.
 上記紅茶抽出物は、完全に発酵処理(酸化発酵処理)されたチャノキの葉(紅茶)に対して、抽出溶媒によって抽出処理を施すことによって得られる。完全発酵されてなる紅茶としては、例えばアッサム紅茶、ダージリン紅茶、セイロン紅茶などが挙げられる。 The black tea extract is obtained by subjecting tea leaves (black tea) that has been completely fermented (oxidative fermentation process) to extraction with an extraction solvent. Examples of completely fermented black tea include Assam black tea, Darjeeling black tea, and Ceylon black tea.
 本実施形態の骨髄幹細胞の分化誘導剤は、ナス果実抽出物をさらに含むことが好ましい。上記の分化誘導剤がナス果実抽出物をさらに含むことによって、より十分に骨髄幹細胞を表皮細胞へ分化誘導できるという利点がある。 It is preferable that the bone marrow stem cell differentiation inducer of this embodiment further includes an eggplant fruit extract. When the differentiation inducer further contains eggplant fruit extract, there is an advantage that differentiation of bone marrow stem cells into epidermal cells can be more fully induced.
 上記ナス果実抽出物は、ナス科ナス属に属するナス(Solanum melongena)の果実に対して抽出溶媒で抽出処理を施すことによって得られるものである。ナスとしては、ミズナスが好ましい。ミズナスの学名は、Solanum melongena (Mizunasu)である。 The eggplant fruit extract is obtained by subjecting an eggplant ( Solanum melongena ) fruit belonging to the genus Solanum to an extraction solvent with an extraction solvent. As eggplant, Mizunas is preferable. The scientific name of Miznas is Solanum melongena (Mizunasu) .
 上記ナス果実抽出物は、ナスの果実に対して、抽出溶媒によって抽出処理を施すことによって得られる。 The above eggplant fruit extract can be obtained by subjecting eggplant fruit to extraction with an extraction solvent.
 上述した各抽出物は、抽出溶媒又は希釈用溶媒を含む抽出液の状態、又は、抽出後の抽出溶媒を除去した乾燥物の状態になり得る。具体的には、各抽出物は、例えば、溶液状、ペースト状、ゲル状、粉末状などの状態になり得る。 Each extract described above can be in the state of an extract containing an extraction solvent or a diluting solvent, or in the form of a dried product from which the extraction solvent has been removed. Specifically, each extract can be in a state of, for example, a solution, a paste, a gel, or a powder.
 上記抽出溶媒としては、水;メタノール、エタノール、プロパノール、ブタノールなどの脂肪族1価アルコール(炭素数1~4であり且つOH基を1つ有する有機化合物(構造異性体含む));グリセリン、プロピレングリコール、1,3-ブチレングリコールなどの脂肪族多価アルコール(炭素数1~5であり且つOH基を複数有する有機化合物);アセトンなどのケトン類;ジエチルエーテル、ジオキサン、アセトニトリル、酢酸エチルエステルなどのエステル類;キシレン、ベンゼン、トルエンなどの芳香族類;クロロホルムなどハロゲン化アルキル類などの有機溶媒が挙げられる。
 これらの抽出溶媒は、1種が単独で、又は2種以上が混合されて用いられ得る。混合抽出溶媒の混合比は、特に限定されるものではなく、適宜調整される。
Examples of the extraction solvent include water; aliphatic monohydric alcohols such as methanol, ethanol, propanol, and butanol (organic compounds having 1 to 4 carbon atoms and one OH group (including structural isomers)); glycerin, propylene Aliphatic polyhydric alcohols such as glycol and 1,3-butylene glycol (organic compounds having 1 to 5 carbon atoms and having a plurality of OH groups); ketones such as acetone; diethyl ether, dioxane, acetonitrile, ethyl acetate, etc. Esters; aromatics such as xylene, benzene and toluene; and organic solvents such as halogenated alkyls such as chloroform.
These extraction solvents may be used alone or in combination of two or more. The mixing ratio of the mixed extraction solvent is not particularly limited, and is appropriately adjusted.
 上記ニーム葉抽出物の抽出溶媒としては、脂肪族多価アルコールを含む溶媒が好ましく、脂肪族多価アルコール(1,3-ブチレングリコール)を50質量%以上含む抽出溶媒がより好ましく、1,3-ブチレングリコールを90質量%以上含む溶媒がさらに好ましい。
 上記紅茶抽出物の抽出溶媒としては、脂肪族1価アルコールを含む溶媒が好ましく、脂肪族1価アルコール(エタノール)を50質量%以上含む抽出溶媒がより好ましく、エタノールを90質量%以上含む溶媒がさらに好ましい。脂肪族1価アルコールで抽出された抽出物は、1,3-ブチレングリコールなどの脂肪族多価アルコールによって溶解されてもよい。
 上記ナス果実抽出物の抽出溶媒としては、水と脂肪族多価アルコール(例えば1,3-ブチレングリコール)とを含む混合溶媒が好ましい。混合溶媒において、水と脂肪族多価アルコール(1,3-ブチレングリコール)との混合比は、7:3(水:脂肪族多価アルコール)が好ましい。
As the extraction solvent for the neem leaf extract, a solvent containing an aliphatic polyhydric alcohol is preferable, an extraction solvent containing 50% by mass or more of an aliphatic polyhydric alcohol (1,3-butylene glycol) is more preferable, and 1,3 -A solvent containing 90% by mass or more of butylene glycol is more preferable.
As an extraction solvent for the black tea extract, a solvent containing an aliphatic monohydric alcohol is preferable, an extraction solvent containing an aliphatic monohydric alcohol (ethanol) at 50% by mass or more is more preferable, and a solvent containing ethanol at 90% by mass or more is preferable. Further preferred. The extract extracted with the aliphatic monohydric alcohol may be dissolved with an aliphatic polyhydric alcohol such as 1,3-butylene glycol.
As an extraction solvent for the eggplant fruit extract, a mixed solvent containing water and an aliphatic polyhydric alcohol (for example, 1,3-butylene glycol) is preferable. In the mixed solvent, the mixing ratio of water and the aliphatic polyhydric alcohol (1,3-butylene glycol) is preferably 7: 3 (water: aliphatic polyhydric alcohol).
 上記抽出処理の方法としては、特に制限されず、従来公知の一般的な抽出方法を採用することができる。抽出処理においては、抽出原料として各植物の抽出部位(葉や果実)をそのまま若しくは乾燥させて用いることができる。また、通常、抽出溶媒量が抽出原料の5~15倍量(質量比)であり、抽出温度が20℃~80℃であり、抽出時間が2時間~3日間である。抽出処理した後においては、必要に応じて、ろ過、脱臭、脱色などの精製処理を行うことができる。 The extraction method is not particularly limited, and a conventionally known general extraction method can be employed. In the extraction process, the extraction site (leaves and fruits) of each plant can be used as it is or after drying as an extraction raw material. Usually, the amount of extraction solvent is 5 to 15 times the mass of the extraction raw material (mass ratio), the extraction temperature is 20 ° C. to 80 ° C., and the extraction time is 2 hours to 3 days. After the extraction treatment, purification treatment such as filtration, deodorization, and decolorization can be performed as necessary.
 上記骨髄幹細胞の分化誘導剤において、紅茶抽出物に対するニーム葉抽出物の質量比(ニーム葉抽出物/紅茶抽出物)は、乾燥物換算で、1/1以上23/1以下であることが好ましく、2/1以上5/1以下であることがより好ましく、3/1以上5/1以下であることがさらに好ましい。
 ナス果実抽出物の質量に対する、ニーム葉抽出物と紅茶抽出物との合計量の質量比(ニーム葉抽出物及び紅茶抽出物/ナス果実抽出物)は、1/1以上7/1以下であることが好ましく、1/1以上5/1以下であることがさらに好ましい。
 なお、乾燥物換算とは、抽出物に含まれる溶媒を抽出物から取り除いた乾燥物の質量に換算することである。
In the bone marrow stem cell differentiation inducer, the mass ratio of neem leaf extract to black tea extract (neem leaf extract / black tea extract) is preferably 1/1 or more and 23/1 or less in terms of dry matter. It is more preferably 2/1 or more and 5/1 or less, and further preferably 3/1 or more and 5/1 or less.
The mass ratio of the total amount of neem leaf extract and black tea extract (neem leaf extract and black tea extract / eggplant extract) to the mass of eggplant fruit extract is 1/1 or more and 7/1 or less. It is preferable that the ratio is 1/1 or more and 5/1 or less.
In addition, dry matter conversion is converting into the mass of the dry matter which removed the solvent contained in an extract from the extract.
 上記骨髄幹細胞の分化誘導剤に含まれる上記各抽出物の濃度は、特に限定されないが、例えば、ニーム葉抽出物の濃度が乾燥物換算で0.0005質量%以上0.075質量%以下であり、紅茶抽出物の濃度が乾燥物換算で0.00015質量%以上0.03質量%以下である。また、ナス果実抽出物の濃度が乾燥物換算で0.0001質量%以上0.015質量%以下である。 The concentration of each of the extracts contained in the bone marrow stem cell differentiation inducer is not particularly limited. For example, the concentration of neem leaf extract is 0.0005% by mass or more and 0.075% by mass or less in terms of dry matter. The concentration of the black tea extract is 0.00015% by mass or more and 0.03% by mass or less in terms of dry matter. Moreover, the density | concentration of eggplant fruit extract is 0.0001 mass% or more and 0.015 mass% or less in conversion of a dry matter.
 上記各抽出物としては、例えば、化粧料用原料、食品添加物として市販されているものを用いることができる。 As each of the above-mentioned extracts, for example, those commercially available as cosmetic raw materials and food additives can be used.
 本実施形態の骨髄幹細胞の分化誘導剤は、上記の各抽出物の他に、水、エタノール、多価アルコール、油分、界面活性剤、増粘剤、防腐剤、pH調整剤、などを含んでもよい。本実施形態の骨髄幹細胞の分化誘導剤は、例えば、液状、ゲル状、クリーム状、固形状などの状態であってもよい。 The differentiation-inducing agent for bone marrow stem cells of the present embodiment may contain water, ethanol, polyhydric alcohol, oil, surfactant, thickener, preservative, pH adjuster, etc. in addition to the above-mentioned extracts. Good. The differentiation-inducing agent for bone marrow stem cells of the present embodiment may be in a liquid, gel-like, cream-like or solid state, for example.
 本実施形態の骨髄幹細胞の分化誘導剤は、例えば、皮膚塗布用又は皮膚貼付用の皮膚外用剤であってもよい。本実施形態の骨髄幹細胞の分化誘導剤は、例えば、化粧料、医薬品、医薬部外品などの用途で用いられてもよい。 The differentiation inducing agent for bone marrow stem cells of the present embodiment may be, for example, an external preparation for skin application or skin application. The bone marrow stem cell differentiation inducer of the present embodiment may be used in applications such as cosmetics, pharmaceuticals, and quasi drugs.
 次に、本発明の表皮改善剤及び皮膚外用剤の実施形態について説明する。本実施形態の表皮改善剤及び皮膚外用剤は、いずれも、骨髄幹細胞の誘引剤と、上記のニーム葉抽出物と、上記の紅茶抽出物とを含むものである。本実施形態の表皮改善剤及び皮膚外用剤は、上記のナス果実抽出物をさらに含むことが好ましい。 Next, embodiments of the epidermis improving agent and the external preparation for skin of the present invention will be described. Each of the epidermis improving agent and the external preparation for skin of the present embodiment contains an attractant for bone marrow stem cells, the above neem leaf extract, and the above black tea extract. It is preferable that the epidermis improving agent and skin external preparation of this embodiment further contain said eggplant fruit extract.
 上記の骨髄幹細胞の誘引剤は、表皮に塗布されることによって、血流中の骨髄幹細胞を表皮に誘引するものであれば、特に限定されない。表皮改善剤又は皮膚外用剤に含まれる上記誘引剤(化合物量及び乾燥物換算量の総量)の濃度は、特に限定されないが、例えば、0.00001質量%以上10質量%以下である。また、表皮改善剤又は皮膚外用剤に含まれるニーム葉抽出物の濃度は、例えば、乾燥物換算で0.0005質量%以上0.075質量%以下であり、紅茶抽出物の濃度は、例えば、乾燥物換算で0.00015質量%以上0.03質量%以下である。 The above-mentioned attractant for bone marrow stem cells is not particularly limited as long as it is applied to the epidermis and attracts bone marrow stem cells in the bloodstream to the epidermis. Although the density | concentration of the said attractant (total amount of compound amount and dry matter conversion amount) contained in an epidermis improving agent or a skin external preparation is not specifically limited, For example, it is 0.00001 mass% or more and 10 mass% or less. Moreover, the concentration of the neem leaf extract contained in the epidermis improving agent or the external preparation for skin is, for example, 0.0005 mass% or more and 0.075 mass% or less in terms of dry matter, and the concentration of the tea extract is, for example, It is 0.00015% by mass or more and 0.03% by mass or less in terms of dry matter.
 上記の誘引剤は、ボダイジュ抽出物、ボタンピ抽出物、クスノハガシワ抽出物、アセンヤク抽出物、パシャンベ抽出物、シンナムタンニンB1、ペンタガロイルグルコース、ボルケンシフラボン、モレロフラボン、ケンフェリトリン、ケルセチン-3,7-ジラムノシド、プロシアニジンA2、プロシアニジンB1、デアセチルサイトカラシンC、エウペニシリウム ルドウィギイ(Eupenicillium ludwigii)の培養物、及び、タラロマイセス トラキスペルムス(Talaromyces trachyspermus)の培養物からなる群より選択された少なくとも1種であることが好ましい。 The above attractants include bodaiju extract, button pipi extract, coxnohagashi extract, asenyaku extract, pashanbe extract, cinnamtannin B1, pentagalloyl glucose, borkensiflavone, moreroflavone, kaempferitrin, quercetin-3 , 7-ziramnoside, procyanidin A2, procyanidin B1, deacetylcytochalasin C, a culture of Eupenicillium ludwigii , and at least one selected from the group consisting of a culture of Talaromyces trachyspermus Preferably there is.
 上記ボダイジュ抽出物は、シナノキ科(Tiliaceae)の植物に対して抽出溶媒によって抽出処理を施すことによって得られるものである。シナノキ科(Tiliaceae)の植物としては、ナツボダイジュ(Tilia platyphyllos Scop.)、フユボダイジュ(Tilia.cordata Mill.)、セイヨウシナノキ(Tilia.europaea L.)、又はその他の近縁植物が挙げられる。なかでも、シナノキ科(Tiliaceae)の植物としては、骨髄幹細胞をより確実に誘引できるという点で、フユボダイジュ(Tilia.cordata Mill.)が好ましい。即ち、ボダイジュ抽出物としては、フユボダイジュ抽出物が好ましい。シナノキ科の植物の抽出部位としては、特に限定されず、例えば、花、果実、樹皮などが挙げられる。なかでも、抽出される部位としては、骨髄幹細胞をより確実に誘引できるという点で、花(花部)が好ましい。
 上記ボダイジュ抽出物の抽出溶媒としては、エタノールと水とを含む抽出溶媒が好ましく、水と50容量%以上のエタノールとを含む抽出溶媒がより好ましい。
The above body extract is obtained by subjecting a plant of the family Tiliaceae to extraction with an extraction solvent. Plants of the family Tiliaceae include tree swordfish ( Tilia platyphyllos Scop. ), Tree swordfish ( Tilia.cordata Mill. ), Linden tree ( Tilia.europaea L. ), or other related plants. Among these, the plant of the family Tiliaceae is preferably a coral mill ( Tilia.cordata Mill. ) In that it can attract bone marrow stem cells more reliably. That is, as the body extract, the body extract is preferable. The extraction site of the lindenaceae plant is not particularly limited, and examples thereof include flowers, fruits, and bark. Among them, the extracted site is preferably a flower (flower part) in that bone marrow stem cells can be attracted more reliably.
As an extraction solvent for the above-mentioned Bodaige extract, an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
 上記ボタンピ抽出物は、ボタン科ボタン属ボタン(Paeonia suffruticosa Andrews)の根皮に対して抽出溶媒によって抽出処理を施すことによって得られるものである。
 上記ボタンピ抽出物の抽出溶媒としては、エタノールと水とを含む抽出溶媒が好ましく、水と50容量%以上のエタノールとを含む抽出溶媒がより好ましい。
The button pi extract is obtained by subjecting the root bark of a button family button ( Paeonia suffruticosa Andrews ) to extraction with an extraction solvent.
As the extraction solvent for the button pi extract, an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
 上記クスノハガシワ抽出物は、トウダイグサ科に属するクスノハガシワ(Mallotus philippinensis)に対して抽出溶媒によって抽出処理を施すことによって得られるものである。クスノハガシワの抽出部位としては、特に限定されず、例えば、葉、枝、材部、樹皮、根などが挙げられる。なかでも、骨髄幹細胞をより確実に誘引できるという点で、樹皮が好ましい。
 上記クスノハガシワ抽出物の抽出溶媒としては、エタノールと水とを含む抽出溶媒が好ましく、水と50容量%以上のエタノールとを含む抽出溶媒がより好ましい。
The above-mentioned Kusunohagashi extract is obtained by subjecting Kusnohagashi wrinkles ( Mallotus philippinensis ) belonging to Euphorbiaceae to extraction treatment with an extraction solvent. There are no particular limitations on the extraction site of Kusunohagashi, and examples include leaves, branches, timber parts, bark, and roots. Of these, bark is preferable because bone marrow stem cells can be attracted more reliably.
As an extraction solvent for the above-mentioned Kusunohagashi extract, an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
 上記アセンヤク抽出物は、アセンヤク(Uncaria gambir)に対して抽出溶媒によって抽出処理を施すことによって得られるものである。アセンヤクの抽出部位としては、特に限定されず、例えば、葉、枝などが挙げられる。アセンヤク抽出物としては、骨髄幹細胞をより確実に誘引できるという点で、葉及び枝の両方に対して抽出溶媒によって抽出処理を施すことによって得られるものが好ましい。
 上記アセンヤク抽出物の抽出溶媒としては、エタノールと水とを含む抽出溶媒が好ましく、水と50容量%以上のエタノールとを含む抽出溶媒がより好ましい。
The asenyaku extract is obtained by subjecting asenyaku ( Uncaria gambir ) to an extraction treatment with an extraction solvent. There are no particular limitations on the extraction site of Acacia yak, and examples include leaves and branches. As the Acacia yak extract, an extract obtained by subjecting both leaves and branches to extraction with an extraction solvent is preferable in that bone marrow stem cells can be attracted more reliably.
As the extraction solvent for the asenyaku extract, an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
 上記パシャンベ抽出物は、ユキノシタ科ヒマラヤユキノシタ属に属するパシャンベ(Pashanbheda)の1種又は2種以上に対して抽出溶媒によって抽出処理を施すことによって得られるものである。パシャンベとしては、Bergenia ligulata(Wall.)Engl.、Bergenia stracheyi(Hook.f.&Thoms.)Engl.、又は、Bergenia ciliata(Haw.)Sternb.などが挙げられる。骨髄幹細胞をより確実に誘引できるという点で、Bergenia ligulata(Wall.)Engl. に対して抽出処理を施すことによって得られるパシャンベ抽出物が好ましい。パシャンベの抽出部位としては、特に限定されないが、骨髄幹細胞をより確実に誘引できるという点で、根茎が好ましい。
 上記パシャンベ抽出物の抽出溶媒としては、エタノールと水とを含む抽出溶媒が好ましく、水と50容量%以上のエタノールとを含む抽出溶媒がより好ましい。
The above-mentioned Pashanbe extract is obtained by subjecting one or more Pashanbheda belonging to the genus Himalaya Yukinoshita to an extraction treatment with an extraction solvent. As pashambe, Bergenia ligulata (Wall.) Engl., Bergenia stracheyi (Hook. F. & Thoms.) Engl. Or Bergenia ciliata (Haw.) Sternb. Etc. A Pashambe extract obtained by subjecting Bergenia ligulata (Wall.) Engl. To extraction treatment is preferable in that it can attract bone marrow stem cells more reliably. The extraction site of the pashambe is not particularly limited, but a rhizome is preferable in that bone marrow stem cells can be attracted more reliably.
As an extraction solvent for the Pasambe extract, an extraction solvent containing ethanol and water is preferable, and an extraction solvent containing water and 50% by volume or more of ethanol is more preferable.
 上記シンナムタンニンB1は、下記式(1)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、シンナムタンニンB1の濃度は、特に限定されず、例えば、0.001~10質量%である。 The cinnamtannin B1 is a compound having a molecular structure represented by the following formula (1). In the above-mentioned epidermis improving agent or external preparation for skin, the concentration of cinnamtannin B1 is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000001
Figure JPOXMLDOC01-appb-C000001
 上記ペンタガロイルグルコースは、下記式(2)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、ペンタガロイルグルコースの濃度は、特に限定されず、例えば、0.001~10質量%である。 The pentagalloyl glucose is a compound having a molecular structure represented by the following formula (2). In the above-mentioned epidermis improving agent or skin external preparation, the concentration of pentagalloyl glucose is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000002
Figure JPOXMLDOC01-appb-C000002
 上記ボルケンシフラボン(タルボタフラボン)[Volkensiflavone(Talbotaflavone)]は、下記式(3)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、ボルケンシフラボンの濃度は、特に限定されず、例えば、0.001~10質量%である。 The above-mentioned Volkensiflavone (Talbotaflavone) is a compound having a molecular structure represented by the following formula (3). In the above-mentioned epidermis improving agent or skin external preparation, the concentration of Borkensiflavone is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000003
Figure JPOXMLDOC01-appb-C000003
 上記モレロフラボン「Morelloflavone」は、下記式(4)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、モレロフラボンの濃度は、特に限定されず、例えば、0.001~10質量%である。 The above morelloflavone “Morelloflavone” is a compound having a molecular structure represented by the following formula (4). In the epidermis improving agent or the external preparation for skin, the concentration of moreroflavone is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000004
Figure JPOXMLDOC01-appb-C000004
 上記ケンフェリトリン[Kaempferitrin](又は、ケンフェロール-3,7-ジラムノシドともいう)は、下記式(5)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、ケンフェリトリンの濃度は、特に限定されず、例えば、0.001~10質量%である。 The kaempferitrin (or kaempferol-3,7-dirhamnoside) is a compound having a molecular structure represented by the following formula (5). In the above-mentioned epidermis improving agent or skin external preparation, the concentration of kaempferitrin is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000005
Figure JPOXMLDOC01-appb-C000005
 上記ケルセチン-3,7-ジラムノシド[Quercetin-3,7,-di-O-α-L-rhamnoside]は、下記式(6)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、ケルセチン-3,7-ジラムノシドの濃度は、特に限定されず、例えば、0.001~10質量%である。 The quercetin-3,7-dirhamnoside [Quercetin-3,7, -di-O-α-L-rhamnoside] is a compound having a molecular structure represented by the following formula (6). In the above-mentioned epidermis improving agent or skin external preparation, the concentration of quercetin-3,7-dirhamnoside is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000006
Figure JPOXMLDOC01-appb-C000006
 上記プロシアニジンA2は、下記式(7)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、プロシアニジンA2の濃度は、特に限定されず、例えば、0.001~10質量%である。 The procyanidin A2 is a compound having a molecular structure represented by the following formula (7). In the above-mentioned epidermis improving agent or skin external preparation, the concentration of procyanidin A2 is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000007
Figure JPOXMLDOC01-appb-C000007
 上記プロシアニジンB1は、下記式(8)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、プロシアニジンB1の濃度は、特に限定されず、例えば、0.001~10質量%である。 The procyanidin B1 is a compound having a molecular structure represented by the following formula (8). In the above-mentioned epidermis improving agent or skin external preparation, the concentration of procyanidin B1 is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000008
Figure JPOXMLDOC01-appb-C000008
 上記デアセチルサイトカラシンCは、下記式(9)の分子構造を有する化合物である。上記表皮改善剤又は皮膚外用剤において、デアセチルサイトカラシンCの濃度は、特に限定されず、例えば、0.001~10質量%である。 The deacetylcytochalasin C is a compound having a molecular structure represented by the following formula (9). In the above-mentioned epidermis improving agent or skin external preparation, the concentration of deacetylcytochalasin C is not particularly limited, and is, for example, 0.001 to 10% by mass.
Figure JPOXMLDOC01-appb-C000009
Figure JPOXMLDOC01-appb-C000009
 上記デアセチルサイトカラシンCは、例えば、子のう菌類微生物に分類される黒彊病菌(メタリジウム アニソプリエ Metarhizium anisopliae)を培養することによって生成された生成物に含まれる。 The deacetylcytochalasin C is included in, for example, a product generated by culturing a black rot fungus ( Metarhizium anisopliae ) classified as a baby fungus microorganism.
 上記エウペニシリウム ルドウィギイ(Eupenicillium ludwigii)の培養物は、例えば、子のう菌類微生物に分類されるエウペニシリウム ルドウィギイ(Eupenicillium ludwigii)を培養することによって生成された生成物に含まれる。 The culture of the above-mentioned Eupenicillium ludwigii is included in the product produced by culturing Eupenicillium ludwigii classified as, for example, an aspergillus fungus microorganism ( Eupenicillium ludwigii ).
 上記タラロマイセス トラキスペルムス(Talaromyces trachyspermus)の培養物は、例えば、不整子のう菌類微生物に分類されるタラロマイセス トラキスペルムス(Talaromyces trachyspermus)を培養することによって生成された生成物に含まれる。 The culture of the above-mentioned Talaromyces trachyspermus ( Talaromyces trachyspermus ) is included in, for example, a product generated by culturing Talaromyces trachyspermus classified as an irregular fungus microorganism.
 本実施形態の表皮改善剤又は皮膚外用剤を、例えば表皮に塗布することによって、骨髄幹細胞を表皮に誘引して表皮細胞に分化させることができ、表皮機能を改善できる。
 表皮は、最も外側から順に、角質層、顆粒層、有棘層、基底層を有しており、基底層に存在する表皮細胞が代謝によって外側に押し上げられ、各層の細胞を形成する。誘引された骨髄幹細胞は、基底層の表皮細胞に分化し得るものである。
By applying the epidermis improving agent or external preparation for skin of the present embodiment to the epidermis, for example, bone marrow stem cells can be attracted to the epidermis and differentiated into epidermal cells, and the epidermal function can be improved.
The epidermis has a stratum corneum layer, a granule layer, a spiny layer, and a basal layer in order from the outermost side, and epidermal cells existing in the basal layer are pushed up by metabolism to form cells of each layer. The induced bone marrow stem cells can differentiate into basal layer epidermal cells.
 本実施形態の表皮改善剤又は皮膚外用剤は、上述した分化誘導剤と同様に、水、エタノール、多価アルコール、油分、界面活性剤、増粘剤、防腐剤、pH調整剤、などをさらに含んでもよい。本実施形態の表皮改善剤は、例えば、液状、ゲル状、クリーム状、固形状などの状態であってもよい。 The epidermis improving agent or external preparation for skin of this embodiment further includes water, ethanol, polyhydric alcohol, oil, surfactant, thickener, preservative, pH adjuster, and the like, as with the differentiation inducer described above. May be included. The skin-improving agent of the present embodiment may be in a liquid, gel-like, cream-like, or solid state, for example.
 本実施形態の表皮改善剤、皮膚外用剤は、例えば、皮膚塗布用又は皮膚貼付用の用途で用いられてもよい。本実施形態の表皮改善剤、皮膚外用剤は、例えば、化粧料、医薬品、医薬部外品などの用途で用いられてもよい。本実施形態の表皮改善剤及び皮膚外用剤は、例えば、後述する表皮改善方法のごとく使用される。 The epidermis improving agent and external preparation for skin of this embodiment may be used, for example, for skin application or skin application. The epidermis improving agent and external preparation for skin of this embodiment may be used in applications such as cosmetics, pharmaceuticals, and quasi drugs. The epidermis improving agent and skin external preparation of this embodiment are used like the epidermis improving method mentioned later, for example.
 続いて、本発明に係る表皮改善方法の実施形態について説明する。 Subsequently, an embodiment of the skin improvement method according to the present invention will be described.
 本実施形態の表皮改善方法は、上記の表皮改善剤又は上記の皮膚外用剤を表皮に塗布することによって骨髄幹細胞を表皮に誘引し、骨髄幹細胞を表皮細胞へ分化させることを備える。
 表皮機能は、加齢に伴って表皮細胞を生み出す基となる表皮幹細胞が減少し、表皮を構成する細胞の数が少なくなったり、細胞の配列が乱れたりすることで悪化する。表皮において表皮幹細胞を増やすことによって、いったん悪化した表皮機能が回復できる。従って、上記の表皮改善剤又は上記の皮膚外用剤によって、骨髄幹細胞を表皮に誘引し、表皮において骨髄幹細胞を表皮細胞へ分化させることで、表皮機能を回復させることができる。
The epidermal improvement method of this embodiment comprises attracting bone marrow stem cells to the epidermis by applying the above-mentioned epidermis improving agent or the above-mentioned external preparation for skin to the epidermis and differentiating the bone marrow stem cells into epidermal cells.
The epidermal function is worsened by a decrease in the number of cells constituting the epidermis and the disruption of the cell arrangement, as the epidermal stem cells that form the epidermal cells decrease with age. By increasing the number of epidermal stem cells in the epidermis, the once deteriorated epidermal function can be recovered. Therefore, the epidermis function can be recovered by attracting bone marrow stem cells to the epidermis by the epidermis improving agent or the above-mentioned external preparation for skin, and differentiating the bone marrow stem cells into epidermal cells in the epidermis.
 上記の表皮改善剤や皮膚外用剤が塗布される表皮の部位は、特に限定されず、例えば角質層、顆粒層、有棘層、又は基底層である。斯かる表皮の部位は、健常部であっても、創傷部であってもよい。 The part of the epidermis to which the above-mentioned epidermis improving agent or external preparation for skin is applied is not particularly limited, and is, for example, the stratum corneum, granule layer, spiny layer, or basal layer. Such a portion of the epidermis may be a healthy part or a wound part.
 上記の表皮改善方法においては、上記の表皮改善剤や皮膚外用剤の誘引剤によって、骨髄幹細胞を表皮に誘引できる。 In the above-mentioned epidermis improvement method, bone marrow stem cells can be attracted to the epidermis by the above-mentioned epidermis improving agent or the skin external preparation attractant.
 例えば、表皮組織に上記の表皮改善剤(皮膚外用剤)を塗布することによって、その表皮組織に、血液中の骨髄幹細胞を誘引できる。 For example, by applying the above-described epidermis improving agent (external preparation for skin) to the epidermal tissue, bone marrow stem cells in the blood can be attracted to the epidermal tissue.
 上記表皮改善方法は、in situにおいてヒト以外の動物で実施できる。また、ヒトにおいて、表皮機能を改善させる美容上の目的で、非治療的に実施できる。美容上の目的としては、例えば、肌のハリを向上させる目的、肌のシワを抑制する目的、肌の乾燥を抑制する目的、肌のくすみを抑制する目的、肌のシミを除去する目的、又は、肌を明るくする目的などが挙げられる。 The above-described method for improving the epidermis can be performed in situ on animals other than humans. In humans, it can be carried out non-therapeutically for the cosmetic purpose of improving the epidermal function. Beauty purposes include, for example, the purpose of improving skin firmness, the purpose of suppressing skin wrinkles, the purpose of suppressing skin drying, the purpose of suppressing skin dullness, the purpose of removing skin spots, or The purpose is to lighten the skin.
 本実施形態の分化誘導剤、表皮改善剤、皮膚外用剤の組成物、及び、表皮改善方法は、上記例示の通りであるが、本発明は、上記例示の実施形態に限定されるものではない。また、本発明では、一般の分化誘導剤、表皮改善剤、皮膚外用剤、及び、表皮改善方法において採用される種々の形態を、本発明の効果を損ねない範囲で採用することができる。 The composition of differentiation-inducing agent, epidermis-improving agent, external preparation for skin and method for improving epidermis according to this embodiment are as exemplified above, but the present invention is not limited to the above-exemplified embodiment. . Moreover, in this invention, the various form employ | adopted in a general differentiation-inducing agent, an epidermis improving agent, an external preparation for skin, and an epidermis improving method can be employ | adopted in the range which does not impair the effect of this invention.
[ニーム葉抽出物]
 製品名「ニームリーフリキッドB」(一丸ファルコス社製)をニーム葉抽出物として用いた。斯かるニーム葉抽出物の製造法は、下記の通りである。
 ニーム(インドセンダン)(Melia azadirachta L. (Meliceae))の葉を加熱処理した後、1,3-ブチレングリコールを抽出溶媒として用いて抽出処理を施し、さらにろ過処理を行ったものをニーム葉抽出物とした。水浴上で5mLのニーム葉抽出物を105℃、6時間で蒸発乾固させた後の蒸発残量から計算すると、ニーム葉抽出物は、乾燥物を1.1質量%含むものであった(固形分濃度換算)。
[Neem leaf extract]
The product name “Neem Leaf Liquid B” (manufactured by Ichimaru Falcos) was used as the neem leaf extract. The method for producing such neem leaf extract is as follows.
Extraction of neem leaf ( Melia azadirachta L. (Meliceae) ) after heat treatment, followed by extraction using 1,3-butylene glycol as an extraction solvent, followed by filtration It was a thing. The neem leaf extract was found to contain 1.1% by mass of dry matter when calculated from the remaining amount of evaporation after 5 mL of neem leaf extract was evaporated to dryness at 105 ° C. for 6 hours on a water bath ( Solid content concentration conversion).
[紅茶抽出物]
 製品名「紅茶リキッド」(一丸ファルコス社製)を紅茶抽出物として用いた。斯かる紅茶抽出物の製造法は、下記の通りである。
 アッサムチャ(Thea sinensis L. var. assamica Pierre (Theaceae))の葉を、エタノールを抽出溶媒として用いて抽出処理し、冷凍処理した後、ろ過処理してろ液を得た。このろ液に1,3-ブチレングリコールを加え、ろ過処理したものを紅茶抽出物(アッサム紅茶抽出物)とした。水浴上で10mLの紅茶抽出物を105℃、6時間で蒸発乾固させた後の蒸発残量から計算すると、紅茶抽出物は、乾燥物を2.4質量%含むものであった(固形分濃度換算)。
[Black tea extract]
The product name “Tea Liquid” (manufactured by Ichimaru Falcos) was used as the tea extract. The manufacturing method of such a black tea extract is as follows.
Assamcha ( Thea sinensis L. var. Assamica Pierre (Theaceae) ) leaves were extracted using ethanol as an extraction solvent, frozen, and filtered to obtain a filtrate. 1,3-butylene glycol was added to this filtrate and the resultant was filtered to obtain a black tea extract (Assam black tea extract). As calculated from the remaining amount of evaporation after 10 mL of black tea extract was evaporated to dryness at 105 ° C. for 6 hours on a water bath, the black tea extract contained 2.4% by mass of the dried product (solid content) Concentration conversion).
[ナス果実抽出物]
 市販されているナス果実抽出物を用いた。斯かるナス果実抽出物の製造法は、下記の通りである。
 ミズナス(Solanum melongena (Mizunasu))の果実の乾燥物100gに、精製水と1,3-ブチレングリコールとの混合液(質量比 水:1,3-BG=7:3)を1200g混合し、80℃で2時間抽出を行った後、ろ過処理を施して、ミズナス果実抽出物を得た。得られたミズナス果実抽出物は、乾燥物を1.01質量%含むものであった(固形分濃度換算)。
[Eggplant fruit extract]
A commercially available eggplant fruit extract was used. The production method of such eggplant fruit extract is as follows.
To 100 g of dried fruit of Solanum melongena (Mizunasu ), 1200 g of a mixture of purified water and 1,3-butylene glycol (mass ratio water: 1,3-BG = 7: 3) was mixed. After extracting at 2 degreeC for 2 hours, the filtration process was performed and the mizunas fruit extract was obtained. The obtained Mizuna fruit extract contained 1.01% by mass of a dried product (in terms of solid content concentration).
(試験例1)
 上記のニーム葉抽出物と、上記の紅茶抽出物とを混合し、抽出物の乾燥物換算の合計量が0.01質量%(四捨五入後の数値)となるように希釈して、試験例1のサンプルを調製した。希釈溶媒として、骨髄幹細胞を表皮細胞へ分化誘導させる分化誘導培地(表皮細胞を長期間培養した培養上清液)を用いた。乾燥物換算で、ニーム葉抽出物と紅茶抽出物との質量比(ニーム葉抽出物/紅茶抽出物)は、四捨五入後の数値で1/1であった。
(Test Example 1)
The above neem leaf extract and the above black tea extract were mixed and diluted such that the total amount of the extract in terms of dry matter was 0.01% by mass (the value after rounding off), and Test Example 1 Samples were prepared. As a dilution solvent, a differentiation induction medium (culture supernatant obtained by culturing epidermal cells for a long period of time) that induces differentiation of bone marrow stem cells into epidermal cells was used. In terms of dry matter, the mass ratio of the neem leaf extract to the black tea extract (neem leaf extract / tea extract) was 1/1 after rounding off.
(試験例2)
 上記のニーム葉抽出物と、上記の紅茶抽出物とを混合し、抽出物の乾燥物換算の合計量が0.01質量%(四捨五入後の数値)となるように希釈して、試験例2のサンプルを調製した。希釈溶媒として、骨髄幹細胞を表皮細胞へ分化誘導させる分化誘導培地(表皮細胞を長期間培養した培養上清液)を用いた。乾燥物換算で、ニーム葉抽出物と紅茶抽出物との質量比(ニーム葉抽出物/紅茶抽出物)は、四捨五入後の数値で2/1であった。
(Test Example 2)
The above neem leaf extract and the above black tea extract were mixed and diluted such that the total amount of the extract in terms of dry matter was 0.01% by mass (number after rounding off), and Test Example 2 Samples were prepared. As a dilution solvent, a differentiation induction medium (culture supernatant obtained by culturing epidermal cells for a long period of time) that induces differentiation of bone marrow stem cells into epidermal cells was used. In terms of dry matter, the mass ratio of neem leaf extract to black tea extract (neem leaf extract / black tea extract) was 2/1 after rounding off.
(試験例3)
 上記のニーム葉抽出物と、上記の紅茶抽出物とを混合し、抽出物の乾燥物換算の合計量が0.01質量%(四捨五入後の数値)となるように希釈して、試験例3のサンプルを調製した。希釈溶媒として、骨髄幹細胞を表皮細胞へ分化誘導させる分化誘導培地(表皮細胞を長期間培養した培養上清液)を用いた。乾燥物換算で、ニーム葉抽出物と紅茶抽出物との質量比(ニーム葉抽出物/紅茶抽出物)は、四捨五入後の数値で3/1であった。
(Test Example 3)
The above neem leaf extract and the above black tea extract were mixed and diluted so that the total amount of the extract in terms of dry matter was 0.01% by mass (number after rounding off), and Test Example 3 Samples were prepared. As a dilution solvent, a differentiation induction medium (culture supernatant obtained by culturing epidermal cells for a long period of time) that induces differentiation of bone marrow stem cells into epidermal cells was used. In terms of dry matter, the mass ratio of the neem leaf extract to the black tea extract (neem leaf extract / tea extract) was 3/1 after rounding off.
(試験例4)
 上記のニーム葉抽出物と、上記の紅茶抽出物とを混合し、抽出物の乾燥物換算の合計量が0.01質量%(四捨五入後の数値)となるように希釈して、試験例4のサンプルを調製した。希釈溶媒として、骨髄幹細胞を表皮細胞へ分化誘導させる分化誘導培地(表皮細胞を長期間培養した培養上清液)を用いた。乾燥物換算で、ニーム葉抽出物と紅茶抽出物との質量比(ニーム葉抽出物/紅茶抽出物)は、四捨五入後の数値で5/1であった。
(Test Example 4)
The above neem leaf extract and the above black tea extract were mixed and diluted so that the total amount of the extract in terms of dry matter was 0.01% by mass (number after rounding off), and Test Example 4 Samples were prepared. As a dilution solvent, a differentiation induction medium (culture supernatant obtained by culturing epidermal cells for a long period of time) that induces differentiation of bone marrow stem cells into epidermal cells was used. In terms of dry matter, the mass ratio of neem leaf extract to black tea extract (neem leaf extract / tea extract) was 5/1 after rounding off.
(試験例5)
 上記のニーム葉抽出物と、上記の紅茶抽出物とを混合し、抽出物の乾燥物換算の合計量が0.01質量%(四捨五入後の数値)となるように希釈して、試験例5のサンプルを調製した。希釈溶媒として、骨髄幹細胞を表皮細胞へ分化誘導させる分化誘導培地(表皮細胞を長期間培養した培養上清液)を用いた。乾燥物換算で、ニーム葉抽出物と紅茶抽出物との質量比(ニーム葉抽出物/紅茶抽出物)は、四捨五入後の数値で23/1であった。
(Test Example 5)
The above neem leaf extract and the above black tea extract were mixed and diluted so that the total amount of the extract in terms of dry matter was 0.01% by mass (number after rounding off), and Test Example 5 Samples were prepared. As a dilution solvent, a differentiation induction medium (culture supernatant obtained by culturing epidermal cells for a long period of time) that induces differentiation of bone marrow stem cells into epidermal cells was used. In terms of dry matter, the mass ratio of neem leaf extract to black tea extract (neem leaf extract / black tea extract) was 23/1 as a value after rounding off.
(試験例6)
 上記のナス果実抽出物を表皮細胞に添加し、24時間培養後に上清を回収することによって、骨髄幹細胞を表皮細胞へ分化させる分化誘導培地(ナス果実抽出物入り)を調製した。この分化誘導培地(ナス果実抽出物入り)を用いて、上記のニーム葉抽出物および紅茶抽出物を、抽出物の乾燥物換算の合計量が0.02質量%となるように希釈し、試験例6のサンプルを調製した。乾燥物換算で、ナス果実抽出物の質量に対する、ニーム葉抽出物及び紅茶抽出物の合計質量の比((ニーム葉抽出物およびアッサム紅茶抽出物)/ミズナス果実抽出物)は、四捨五入後の数値で7/1であった。
(Test Example 6)
The above-described eggplant fruit extract was added to epidermal cells, and the supernatant was collected after 24 hours of culture to prepare a differentiation induction medium (with eggplant fruit extract) for differentiating bone marrow stem cells into epidermal cells. Using this differentiation-inducing medium (with eggplant fruit extract), the above neem leaf extract and black tea extract were diluted so that the total amount of the extract in terms of dry matter was 0.02% by mass. Six samples were prepared. The ratio of the total mass of neem leaf extract and black tea extract ((neem leaf extract and Assam black tea extract) / Miznas fruit extract) to the mass of eggplant fruit extract in terms of dry matter is the value after rounding off. It was 7/1.
(試験例7)
 上記のナス果実抽出物を表皮細胞に添加し、24時間培養後に上清を回収することによって、骨髄幹細胞を表皮細胞へ分化させる分化誘導培地(ナス果実抽出物入り)を調製した。この分化誘導培地(ナス果実抽出物入り)を用いて、上記のニーム葉抽出物および紅茶抽出物を、抽出物の乾燥物換算の合計量が0.02質量%となるように希釈し、試験例7のサンプルを調製した。乾燥物換算で、ナス果実抽出物の質量に対する、ニーム葉抽出物及び紅茶抽出物の合計質量の比((ニーム葉抽出物およびアッサム紅茶抽出物)/ミズナス果実抽出物)は、四捨五入後の数値で4/1であった。
(Test Example 7)
The above-described eggplant fruit extract was added to epidermal cells, and the supernatant was collected after 24 hours of culture to prepare a differentiation induction medium (with eggplant fruit extract) for differentiating bone marrow stem cells into epidermal cells. Using this differentiation-inducing medium (with eggplant fruit extract), the above neem leaf extract and black tea extract were diluted so that the total amount of the extract in terms of dry matter was 0.02% by mass. Seven samples were prepared. The ratio of the total mass of neem leaf extract and black tea extract ((neem leaf extract and Assam black tea extract) / Miznas fruit extract) to the mass of eggplant fruit extract in terms of dry matter is the value after rounding off. It was 4/1.
(試験例8)
 上記のナス果実抽出物を表皮細胞に添加し、24時間培養後に上清を回収することによって、骨髄幹細胞を表皮細胞へ分化させる分化誘導培地(ナス果実抽出物入り)を調製した。この分化誘導培地(ナス果実抽出物入り)を用いて、上記のニーム葉抽出物および紅茶抽出物を、抽出物の乾燥物換算の合計量が0.02質量%となるように希釈し、試験例8のサンプルを調製した。乾燥物換算で、ナス果実抽出物の質量に対する、ニーム葉抽出物及び紅茶抽出物の合計質量の比((ニーム葉抽出物およびアッサム紅茶抽出物)/ミズナス果実抽出物)は、四捨五入後の数値で1/1であった。
(Test Example 8)
The above-described eggplant fruit extract was added to epidermal cells, and the supernatant was collected after 24 hours of culture to prepare a differentiation induction medium (with eggplant fruit extract) for differentiating bone marrow stem cells into epidermal cells. Using this differentiation-inducing medium (with eggplant fruit extract), the above neem leaf extract and black tea extract were diluted so that the total amount of the extract in terms of dry matter was 0.02% by mass. Eight samples were prepared. The ratio of the total mass of neem leaf extract and black tea extract ((neem leaf extract and Assam black tea extract) / Miznas fruit extract) to the mass of eggplant fruit extract in terms of dry matter is the value after rounding off. It was 1/1.
(参考例1、参考例2)
 上記のニーム葉抽出物の乾燥物換算の量が、それぞれ0.006質量%、0.011質量%となるように、上記のニーム葉抽出物を希釈して、参考例1及び参考例2のサンプルを調製した。希釈溶媒として、骨髄幹細胞を表皮細胞へ分化誘導させる分化誘導培地(表皮細胞を長期間培養した培養上清液)を用いた。
(Reference Example 1, Reference Example 2)
The neem leaf extract was diluted so that the amount of the neem leaf extract in terms of dry matter was 0.006% by mass and 0.011% by mass, respectively. Samples were prepared. As a dilution solvent, a differentiation induction medium (culture supernatant obtained by culturing epidermal cells for a long period of time) that induces differentiation of bone marrow stem cells into epidermal cells was used.
(参考例3~5)
 上記の紅茶抽出物の乾燥物換算の量が、それぞれ0.0002質量%、0.0024質量%、0.0036質量%となるように、上記の紅茶抽出物を希釈して、参考例3~5のサンプルを調製した。希釈溶媒として、骨髄幹細胞を表皮細胞へ分化誘導させる分化誘導培地(表皮細胞を長期間培養した培養上清液)を用いた。
(Reference Examples 3 to 5)
The above black tea extract was diluted so that the dry tea equivalents of the black tea extract were 0.0002 mass%, 0.0024 mass%, and 0.0036 mass%, respectively. Five samples were prepared. As a dilution solvent, a differentiation induction medium (culture supernatant obtained by culturing epidermal cells for a long period of time) that induces differentiation of bone marrow stem cells into epidermal cells was used.
<分化誘導に関わる評価試験>
 96ウェルプレートに骨髄幹細胞を6,000 cells/ウェルで播種し、3日間培養した。別途、表皮細胞を直径10cmシャーレに播種し、9割コンフルエントに達したときに新しい培地に交換し、24時間培養後に上清培養液を回収した。回収した上清培養液を遠心分離し、ろ過することによって得られた溶液を、分化誘導培地(骨髄幹細胞を表皮細胞へ分化誘導させる分化誘導培地)とした。また、ナス果実抽出物を用いた試験においては、ナス果実抽出物を表皮細胞に添加し、培養24時間後に上清を回収し、遠心分離、ろ過によって得られた溶液を分化誘導培地とした。各試験に応じて、調製した分化誘導培地を用いてニーム葉抽出物、紅茶抽出物を希釈し、培養した骨髄幹細胞に添加した後、9~10日間分化誘導培養を行った。培養後、免疫細胞染色によって、分化度合いを評価した。分化誘導させた骨髄幹細胞(MSC)を4%パラホルムアルデヒド(WAKO社製)で固定後、PBS(-)で3回洗浄した。その後、0.25%Triton溶液で処理し、TBS-Tで洗浄した。さらに、2%BSA/PBS(-)(SIGMA社製)溶液による反応を室温で1時間行い、引き続き一次抗体による反応を4℃で終夜行った。反応後に一次抗体溶液を除去し、TBS-Tで5回洗浄後、二次抗体反応およびHoechst溶液による反応を室温で30分間行った。二次抗体溶液を除去後、TBS-Tで5回洗浄し、PBS(-)に置換した後に、分化度合いを観察した。免疫細胞染色の一次抗体においては、表皮細胞のみに発現するケラチン14(K14)抗体と、ケラチン5(K5)抗体とを使用した。染色度合いは、In cell analyzer装置(GE Healthcare社)を用いて染色画像の数値化(Dens level sum × Area) / Hochest)を施し、その値で評価した。
<Evaluation test for differentiation induction>
Bone marrow stem cells were seeded at 6,000 cells / well in a 96-well plate and cultured for 3 days. Separately, epidermal cells were seeded in a petri dish having a diameter of 10 cm, and when 90% confluent was reached, the medium was replaced with a new medium, and the supernatant culture solution was collected after 24 hours of culture. The solution obtained by centrifuging and filtering the collected supernatant culture solution was used as a differentiation induction medium (differentiation induction medium for inducing differentiation of bone marrow stem cells into epidermal cells). In the test using eggplant fruit extract, eggplant fruit extract was added to epidermal cells, the supernatant was collected after 24 hours of culture, and the solution obtained by centrifugation and filtration was used as a differentiation-inducing medium. According to each test, neem leaf extract and black tea extract were diluted using the prepared differentiation induction medium and added to cultured bone marrow stem cells, and then differentiation induction culture was performed for 9 to 10 days. After culturing, the degree of differentiation was evaluated by immune cell staining. Differentiation-induced bone marrow stem cells (MSC) were fixed with 4% paraformaldehyde (manufactured by WAKO), and then washed three times with PBS (−). Thereafter, it was treated with a 0.25% Triton solution and washed with TBS-T. Furthermore, a reaction with a 2% BSA / PBS (−) (manufactured by SIGMA) solution was carried out at room temperature for 1 hour, followed by a reaction with a primary antibody at 4 ° C. overnight. After the reaction, the primary antibody solution was removed, and after washing 5 times with TBS-T, the secondary antibody reaction and the reaction with Hoechst solution were performed at room temperature for 30 minutes. After removing the secondary antibody solution, the plate was washed 5 times with TBS-T and replaced with PBS (−), and the degree of differentiation was observed. As the primary antibody for immune cell staining, keratin 14 (K14) antibody and keratin 5 (K5) antibody expressed only in epidermal cells were used. The degree of staining was evaluated by using a numerical value of the stained image (Dens level sum × Area) / Hoches) using an In cell analyzer device (GE Healthcare).
 試験例1~5を用いた分化誘導に関わる評価試験結果を図1に示す。参考例1、2における評価試験結果を図2A及び図2Bに示す。参考例3~5における評価試験結果を図3A及び図3Bに示す。ナス果実抽出物を単独で用いた評価試験結果を図4A及び図4Bに示す。試験例3、6~8の評価試験結果を図5に示す。各図における結果から把握されるように、ニーム葉抽出物と紅茶抽出物とを含む骨髄幹細胞の分化誘導剤によって、骨髄幹細胞を表皮細胞へ分化させることができた。ニーム葉抽出物と紅茶抽出物とが特定の質量比(例えば、乾燥物換算で、ニーム葉抽出物/紅茶抽出物=2:1~5:1の範囲、より好ましくは3:1~5:1の範囲)のときに、分化誘導性能が顕著に発揮された。この効果は、ニーム葉抽出物と紅茶抽出物との相乗的な効果である。
 また、図5に示されるように、ニーム葉抽出物及び紅茶抽出物に、さらにナス果実抽出物を組み合わせることによって、分化誘導性能をさらに向上させることができた。ナス果実抽出物は、表皮細胞に対して分化誘導因子の分泌を増やす作用を有すると考えられる。
The evaluation test results relating to differentiation induction using Test Examples 1 to 5 are shown in FIG. The evaluation test results in Reference Examples 1 and 2 are shown in FIGS. 2A and 2B. The evaluation test results in Reference Examples 3 to 5 are shown in FIGS. 3A and 3B. The evaluation test results using the eggplant fruit extract alone are shown in FIGS. 4A and 4B. The evaluation test results of Test Examples 3 and 6 to 8 are shown in FIG. As can be seen from the results in each figure, bone marrow stem cells could be differentiated into epidermal cells by using a bone marrow stem cell differentiation inducer containing neem leaf extract and black tea extract. Neem leaf extract and black tea extract have a specific mass ratio (for example, in terms of dry matter, neem leaf extract / black tea extract = 2: 1 to 5: 1, more preferably 3: 1 to 5: 1), the differentiation-inducing performance was remarkably exhibited. This effect is a synergistic effect of the neem leaf extract and the black tea extract.
Moreover, as shown in FIG. 5, differentiation induction performance could be further improved by further combining eggplant fruit extract with neem leaf extract and black tea extract. Eggplant fruit extract is considered to have an action of increasing secretion of differentiation-inducing factors for epidermal cells.
 下記のようにして骨髄幹細胞の誘引剤を調製した。調製した誘引剤を使用して、生体外における細胞誘引試験を行った。 A bone marrow stem cell attractant was prepared as follows. Using the prepared attractant, an in vitro cell attraction test was performed.
「誘引剤1」
 誘引剤1のボダイジュ抽出物(フユボダイジュ抽出物)を調製した。詳しくは、フユボダイジュ(Tilia.cordata Mill)の花を乾燥して細かく砕いたもの100gに50容量%エタノール水溶液1Lを加え、室温(20℃)にて3日間抽出操作をおこない、さらにろ過処理を行った。そして、ろ過した液から減圧乾燥により乾燥物を得て、この乾燥物を1,3-ブチレングリコールで希釈してフユボダイジュ抽出物を調製した。このボダイジュ抽出物は、減圧乾燥によって抽出溶媒を除去したあとの乾燥物質量から計算すると、乾燥物を0.45質量%含むものであった。
"Attractant 1"
A Bodaiju extract of Attractant 1 (Fuyubodaiju extract) was prepared. Specifically, 1L of a 50% ethanol aqueous solution is added to 100g of dried and finely crushed flowers of Tilia.cordata Mill , followed by extraction at room temperature (20 ° C) for 3 days, followed by filtration. went. Then, a dried product was obtained from the filtered solution by drying under reduced pressure, and this dried product was diluted with 1,3-butylene glycol to prepare a jujube extract. When calculated from the amount of the dry substance after the extraction solvent was removed by drying under reduced pressure, this body extract contained 0.45% by mass of the dried product.
「誘引剤2」
 誘引剤2のボタンピ抽出物を調製した。詳しくは、ボタン(Paeonia suffruticosa Andrews)の根皮を乾燥して細かく砕いたもの100gに50容量%エタノール水溶液1Lを加え、室温(20℃)にて3日間抽出操作をおこない、さらにろ過処理を行った。そして、ろ過した液から減圧乾燥により乾燥物を得て、この乾燥物を1,3-ブチレングリコールで希釈してボタンピ抽出物を調製した。このボタンピ抽出物は、減圧乾燥によって抽出溶媒を除去したあとの乾燥物質量から計算すると、乾燥物を0.90質量%含むものであった。
"Attractant 2"
A button pea extract of attractant 2 was prepared. In detail, 1L of 50 vol% ethanol aqueous solution was added to 100g of dried root bark of a button ( Paeonia suffruticosa Andrews ), followed by extraction at room temperature (20 ° C) for 3 days, followed by filtration. It was. A dried product was obtained from the filtered solution by drying under reduced pressure, and the dried product was diluted with 1,3-butylene glycol to prepare a button pi extract. This button pi extract, when calculated from the amount of dry substance after removal of the extraction solvent by drying under reduced pressure, contained 0.90% by mass of the dried product.
「誘引剤3」
 誘引剤3のクスノハガシワ抽出物を調製した。詳しくは、クスノハガシワ(Mallotus philippinensis Mueller-Argoviensis)の樹皮を乾燥して細かく砕いたもの200gに50容量%エタノール水溶液2Lを加え、60~80℃を保ちつつ2日間抽出操作をおこない、さらにろ過処理を行った。そして、ろ過した液から減圧乾燥により乾燥物を得て、この乾燥物を1,3-ブチレングリコールで希釈してクスノハガシワ抽出物を調製した。このクスノハガシワ抽出物は、減圧乾燥によって抽出溶媒を除去したあとの乾燥物質量から計算すると、乾燥物を0.20質量%含むものであった。
"Attractant 3"
A Kusunohagashi extract of attractant 3 was prepared. For details, add 2L of 50% ethanol aqueous solution to 200g of dried and finely crushed bark of Kusonohagashi ( Mallotus philippinensis Mueller-Argoviensis ), and perform extraction for 2 days while maintaining 60-80 ° C. went. Then, a dried product was obtained from the filtered liquid by drying under reduced pressure, and this dried product was diluted with 1,3-butylene glycol to prepare a Kusunohagashi extract. This Kusunohagashi extract contained 0.20% by mass of the dried product, as calculated from the amount of dry substance after the extraction solvent was removed by drying under reduced pressure.
「誘引剤4」
 誘引剤4のアセンヤク抽出物を調製した。詳しくは、アセンヤク(Uncaria gambir Roxburgh)の葉及び若枝を乾燥して細かく砕いたもの100gに50容量%エタノール水溶液2Lを加え、撹拌しながら50~70℃を保ちつつ3時間抽出操作をおこない、さらにろ過処理を行った。そして、ろ過した液から減圧乾燥により乾燥物を得て、この乾燥物を1,3-ブチレングリコールで希釈してアセンヤク抽出物を調製した。このアセンヤク抽出物は、減圧乾燥によって抽出溶媒を除去したあとの乾燥物質量から計算すると、乾燥物を4.10質量%含むものであった。
"Attractant 4"
An asenyaku extract of attractant 4 was prepared. Specifically, 2 L of a 50% ethanol aqueous solution was added to 100 g of dried and finely crushed leaves and young branches of Acacia yam ( Uncaria gambir Roxburgh ), and the extraction operation was performed for 3 hours while maintaining 50 to 70 ° C. with stirring. Filtration was performed. A dried product was obtained from the filtered solution by drying under reduced pressure, and the dried product was diluted with 1,3-butylene glycol to prepare an asenyaku extract. This asenyaku extract was found to contain 4.10% by mass of the dried product when calculated from the amount of dry substance after the extraction solvent was removed by drying under reduced pressure.
「誘引剤5」
 誘引剤5のパシャンベ抽出物を調製した。詳しくは、パシャンベ(Bergenia ligulata(Wall.)Engl.)の根茎を乾燥して細かく砕いたもの200gに50容量%エタノール水溶液3kgを加え、撹拌しながら50℃にて8時間抽出操作を行った。粗抽出物を冷却、ろ過操作した後、濃縮し、合成吸着体(商品名「ダイヤイオンHP-20」 三菱化学社製)を充填したカラムに通液した。そして、水洗を行い、30容量%エタノール水溶液にて溶出させた溶出液を減圧乾燥後、1,3-ブチレングリコールに再溶解してパシャンベ抽出物を調製した。このパシャンベ抽出物は、減圧乾燥によって抽出溶媒を除去したあとの乾燥物質量から計算すると、乾燥物を0.50質量%含むものであった。
"Attractant 5"
A pashambe extract of attractant 5 was prepared. Specifically, 3 kg of a 50 vol% ethanol aqueous solution was added to 200 g of dried and finely crushed rhizomes of Pashambe ( Bergenia ligulata (Wall.) Engl. ), And extraction was performed at 50 ° C. for 8 hours while stirring. The crude extract was cooled, filtered, concentrated, and passed through a column packed with a synthetic adsorbent (trade name “Diaion HP-20” manufactured by Mitsubishi Chemical Corporation). After washing with water, the eluate eluted with a 30% by volume ethanol aqueous solution was dried under reduced pressure and redissolved in 1,3-butylene glycol to prepare a Pashambe extract. When calculated from the amount of dry substance after the extraction solvent was removed by drying under reduced pressure, this Pashambe extract contained 0.50% by mass of the dried product.
「誘引剤6」
 誘引剤6として、市販のシンナムタンニンB1を使用した。
「誘引剤7」
 誘引剤7として、市販のペンタガロイルグルコースを使用した。
「誘引剤8」
 誘引剤8として、市販のボルケンシフラボンを使用した。
「誘引剤9」
 誘引剤9として、市販のモレロフラボンを使用した。
「誘引剤10」
 誘引剤10として、市販のケンフェリトリンを使用した。
「誘引剤11」
 誘引剤11として、市販のケルセチン-3,7-ジラムノシドを使用した。
「誘引剤12」
 誘引剤12として、市販のプロシアニジンA2を使用した。
「誘引剤13」
 誘引剤13として、市販のプロシアニジンB1を使用した。
"Attractant 6"
As attractant 6, commercially available cinnamtannin B1 was used.
"Attractant 7"
As the attractant 7, commercially available pentagalloyl glucose was used.
"Attractant 8"
As attractant 8, commercially available Borkensiflavone was used.
"Attractant 9"
As the attractant 9, a commercially available moreroflavone was used.
"Attractant 10"
As the attractant 10, commercially available kaempferitrin was used.
"Attractant 11"
As the attractant 11, commercially available quercetin-3,7-dirhamnoside was used.
"Attractant 12"
As the attractant 12, commercially available procyanidin A2 was used.
"Attractant 13"
As the attractant 13, commercially available procyanidin B1 was used.
「誘引剤14」
 下記に示すように、デアセチルサイトカラシンCを含む誘引剤を製造した。
 即ち、黒彊病菌(メタリジウム アニソプリエ(Metarhizium anisopliae))を培養し、培養後の培地及び菌体を含む粗培養物を得た。この粗培養物に対して抽出処理を施すことにより培養抽出物を調製した。詳細について、以下に説明する。
 まず、メタリジウム アニソプリエ(Metarhizium anisopliae)の前培養を行うために、グリセロールストックから取り出した種菌を下記の培養条件に従って培養した。
・前培養条件:温度28℃、40日間
・前培養培地組成:下記に示すLCA寒天培地
      グルコース        1g
      KHPO        1g
      MgSO・7HO    0.2g
      KCl          0.2g
      NaNO         2g
      バクト-酵母エキス     0.2g
          (Becton, Dickinson and Company社製)
      寒天(和光純薬社製)   20g
      水道水          1L
      NaOH         64.8mg
 前培養後、菌糸体を含む寒天培地をストローで打ち抜いた。一方、3.5mLの滅菌水道水を15mL容量の遠心管に分注した。打ち抜いた寒天培地の5片を遠心管に入れ、綿棒で寒天培地を押し潰して懸濁液を調製した。
 続いて、本培養のための培地として、50mL容量の遠心管中に下記組成の本培養培地を作製し、本培養用の遠心管に1mLの上記懸濁液を添加し、下記の培養条件で本培養した。
・本培養条件:温度28℃、2週間
・本培養培地組成:下記に示す固形状培地
      野菜ジュース            10mL
         (キャンベル・スープ・カンパニー社製 商品名「V8ジュース」)
      オートミール             3g
         (雪印乳業(クエーカー)社製)
 本培養後の遠心管に抽出溶媒としての80容量%アセトン水溶液を加え、粗培養物に対して抽出溶媒による抽出処理を行った。
 詳しくは、遠心管に抽出溶媒を加えた後、遠心管を激しく上下に振って内容物を撹拌し、室温で30分間静置した。その後、遠心管に対して回転数3500rpm、23℃で5分間の遠心分離操作を行い、遠心分離後の上清約15mLをデカンテーションにより回収した。
 続いて、上清をドラフトで約15時間静置することにより抽出溶媒を揮発させて濃縮した後、濃縮された上清が約10mLになるまで-20℃で保存した。
 保存した後の上清をマイクロチューブに入れ、13,000rpmの遠心分離により、沈殿物と沈殿物以外のサンプル液とを得た。
 サンプル液の225.6μL(本培養ブロス200μLに相当)を遠心エバポレーターで乾固させ、-20℃で保存した。乾固させたサンプルを80容量%メタノール水溶液100μLに溶解し、ボルテックスミキサーを用いて30分間懸濁させた後、13,500rpm、4℃、5分間の遠心分離により上清を得て、培養抽出物を調製し、誘引剤を製造した。
 該誘引剤は、溶媒を除去したあとの乾燥物質量から計算すると、乾燥物を15質量%含むものであった。
 上記のごとく製造した誘引剤14がデアセチルサイトカラシンCを含むことは、核磁気共鳴法(NMR)、質量分析(MS)法によって確認した。
"Attractant 14"
As shown below, an attractant containing deacetylcytochalasin C was prepared.
That is, black rot fungus ( Metarhizium anisopliae ) was cultured, and a crude culture containing the cultured medium and cells was obtained. A culture extract was prepared by subjecting this crude culture to an extraction treatment. Details will be described below.
First, in order to perform pre-culture of Metarhizium anisopliae , inoculum extracted from the glycerol stock was cultured according to the following culture conditions.
Pre-culture conditions: Temperature 28 ° C., 40 days Pre-culture medium composition: LCA agar medium shown below 1 g glucose
KH 2 PO 4 1g
MgSO 4 · 7H 2 O 0.2g
KCl 0.2g
NaNO 3 2g
Bacto-yeast extract 0.2g
(Becton, Dickinson and Company)
Agar (Wako Pure Chemical Industries) 20g
Tap water 1L
NaOH 64.8mg
After pre-culture, the agar medium containing mycelium was punched with a straw. Meanwhile, 3.5 mL of sterilized tap water was dispensed into a 15 mL centrifuge tube. Five pieces of the punched agar medium were placed in a centrifuge tube, and the agar medium was crushed with a cotton swab to prepare a suspension.
Subsequently, as a medium for main culture, a main culture medium having the following composition is prepared in a 50 mL capacity centrifuge tube, and 1 mL of the above suspension is added to the main culture centrifuge tube. Main culture was performed.
・ Main culture conditions: Temperature 28 ° C., 2 weeks ・ Main culture medium composition: Solid medium shown below Vegetable juice 10 mL
(Product name “V8 Juice” manufactured by Campbell Soup Company)
Oatmeal 3g
(Snow Brand Milk Products (Quaker))
An 80 vol% acetone aqueous solution as an extraction solvent was added to the centrifuge tube after the main culture, and the crude culture was extracted with the extraction solvent.
Specifically, after adding the extraction solvent to the centrifuge tube, the centrifuge tube was vigorously shaken up and down to stir the contents, and allowed to stand at room temperature for 30 minutes. Thereafter, the centrifuge tube was centrifuged at 3500 rpm and 23 ° C. for 5 minutes, and about 15 mL of the supernatant after centrifugation was collected by decantation.
Subsequently, the supernatant was allowed to stand for about 15 hours in a draft to evaporate the extraction solvent and concentrated, and then stored at −20 ° C. until the concentrated supernatant reached about 10 mL.
The stored supernatant was placed in a microtube, and a precipitate and a sample solution other than the precipitate were obtained by centrifugation at 13,000 rpm.
225.6 μL of the sample solution (corresponding to 200 μL of main culture broth) was dried to dryness with a centrifugal evaporator and stored at −20 ° C. The dried sample is dissolved in 100 μL of 80% by volume methanol aqueous solution and suspended for 30 minutes using a vortex mixer, and then the supernatant is obtained by centrifugation at 13,500 rpm, 4 ° C. for 5 minutes, followed by culture extraction A product was prepared and an attractant was produced.
The attractant contained 15% by mass of a dried product as calculated from the amount of dry substance after removing the solvent.
It was confirmed by nuclear magnetic resonance (NMR) and mass spectrometry (MS) that the attractant 14 produced as described above contained deacetylcytochalasin C.
「誘引剤15」(Eupenicillium ludwigiiの培養物)
 エウペニシリウム ルドウィギイ(Eupenicillium ludwigii)を培養することにより、培養後の培地及び菌体を含む粗培養物を得た。粗培養物に対して抽出処理を施して培養抽出物を得て、誘引剤15を製造した。その詳細について以下に説明する。
 まず、グリセロールストックから取り出した菌体を傾斜培地(麦芽エキス寒天培地(MA培地))に植え付け、1週間の前培養を行った。次に、前培養後の菌体を白金耳で取り出し、5mLの滅菌生理食塩水に懸濁させた後、下記組成の培地が入った150mL容量のポリプロピレン製フラスコ内に懸濁液の全部を入れて植菌し、静置培養(25℃、12日間)した。
・培地組成
  そば粉      10g
  SB溶液     10mL (計20g/フラスコ)
・SB溶液の組成
      酒石酸ナトリウム           0.005%
      KHPO              0.005%
      MgSO・7HO          0.005%
      FeSO・7HO          0.0005%
      ZnSO・7HO          0.0005%
      酵母エキス(オリエンタル酵母社製)  0.01%
      水                  残部
 続いて、培養後の培地及び菌体の混合液(粗培養物)240μLに対して、抽出溶媒としての100%ブタノール(100μL)を用いて抽出処理を施し、遠心分離により分離した上清を凍結乾燥して溶媒を除去した。
 さらに、ブタノールで抽出した後の凍結乾燥物に50μLのメタノールを加え、ボルテックスミキサーによって30分間撹拌して懸濁させた後、13,500rpm、4℃、5分間の遠心分離によって上清を得た。
 このようにして、エウペニシリウム ルドウィギイ(Eupenicillium ludwigii)の培養抽出物を含む誘引剤を製造した。
 該誘引剤は、溶媒を除去したあとの乾燥物質量から計算すると、乾燥物を2質量%含むものであった。
" Attractant 15" (culture of Eupenicillium ludwigii )
By culturing Eupenicillium ludwigii , a crude culture containing the cultured medium and cells was obtained. The crude culture was subjected to an extraction treatment to obtain a culture extract, and the attractant 15 was produced. Details thereof will be described below.
First, the microbial cells taken out from the glycerol stock were planted in an inclined medium (malt extract agar medium (MA medium)) and pre-cultured for 1 week. Next, the cells after pre-culture are removed with a platinum loop and suspended in 5 mL of sterile physiological saline, and then the entire suspension is put into a 150 mL polypropylene flask containing a medium having the following composition. Inoculated and statically cultured (25 ° C., 12 days).
・ Medium composition Buckwheat flour 10g
SB solution 10mL (total 20g / flask)
-Composition of SB solution Sodium tartrate 0.005%
KH 2 PO 4 0.005%
MgSO 4 · 7H 2 O 0.005%
FeSO 4 · 7H 2 O 0.0005%
ZnSO 4 · 7H 2 O 0.0005%
Yeast extract (Oriental Yeast Co., Ltd.) 0.01%
Water remainder Subsequently, the supernatant after separation by centrifugation was performed on 240 μL of the culture medium and bacterial cell mixture (crude culture) after culture using 100% butanol (100 μL) as an extraction solvent. Was lyophilized to remove the solvent.
Furthermore, 50 μL of methanol was added to the lyophilized product after extraction with butanol, and the mixture was suspended by stirring for 30 minutes with a vortex mixer, and then a supernatant was obtained by centrifugation at 13,500 rpm, 4 ° C. for 5 minutes. .
In this way, an attractant containing a culture extract of Eupenicillium ludwigii was produced.
The attractant contained 2% by mass of the dried product when calculated from the amount of dry substance after removing the solvent.
「誘引剤16」(Talaromyces trachyspermusの培養物)
 エウペニシリウム ルドウィギイ(Eupenicillium ludwigii)に代えて、タラロマイセス トラキスペルムス(Talaromyces trachyspermus)を用いた点以外は、誘引剤15と同様にして誘引剤16を製造した。該誘引剤は、乾燥物を2質量%含むものであった。
Attractant 16” (culture of Talaromyces trachyspermus )
The attractant 16 was produced in the same manner as the attractant 15 except that Talaromyces trachyspermus was used instead of Eupenicillium ludwigii . The attractant contained 2% by mass of a dried product.
<生体外における細胞誘引試験>
 図7は、該試験方法の様子を模式的に示したものである。以下、図7を参照しつつ試験方法の詳細を説明する。
 上記の各誘引剤を試験用サンプルとして用意した。誘引剤の濃度が所定の各濃度(1%や0.1%など)となるように希釈したものを、試験用サンプルとして用意した。
 一方、陰性対照サンプルとして、DMEM(ダルベッコ変法イーグル培地)「FBS(-)、P/S(-)」を用意した。
 また、陽性対照サンプルとして、20ng/mL PDGF-BB(血小板由来成長因子 PEPRO TECH社製)濃度のDMEM溶液を用意した。
 まず、マウス骨髄幹細胞(以下、mMSCともいう)をコンフルエントまで培養して回収し、10% FBS/DMEM「P/S(-)」で1×107cells/mlとなるように懸濁し、細胞懸濁液を用意した。なお、FBSは、10%ウシ胎児血清を示し、P/Sは、100ユニットペニシリン及び0.1mg/mLストレプトマイシンを示している。また(-)の記号は、配合していないことを示している。
 次に、複数の独立したウェルを備え、図7における(a)に示すようにメンブレンMによってウェルが上部ウェルPと下部ウェルQとに仕切られているボイデンチャンバーB(Neuro Probe社製)を用意した。各試験用サンプルのいずれか1種と陰性対照サンプル及び陽性対照サンプルとが同一のボイデンチャンバーBにおいて試験できるように設定し、該チャンバーBの各下部ウェルに各サンプルをそれぞれ28μLずつアプライした。ボイデンチャンバーBのメンブレンMとしては、商品名「Polycarbonate Membranes」(Neuro Probe社製 細孔サイズ8μm)を用いた。
 続いて、上部ウェルPに上記細胞懸濁液を50μLずつ播種し、37℃、5%COの条件下で4時間培養した(図7における(b)を参照)。
 4時間培養後、図7における(c)に示すように、移動していないmMSCを付属のフィルターワイパーRではぎ取り、メンブレンMの下側へ移動したmMSCのみをディフ・クイック染色(Sysmex社製キットを使用)によって染色した。
 そして、染色像をデジタル化してコンピュータに取り込み、画像を黒と白に2値化すべく青色に染色された部分が白色になるように変換したうえで、各ウェル範囲内の輝度の平均値を画像編集ソフトウェア(商品名「フォトショップ」)の機能を用いて測定した。陰性対照サンプルおよび陽性対照サンプルにおける輝度を各試験用サンプルにおける輝度と比較することによって、各誘引剤のmMSC誘引活性を評価した。
<In vitro cell attraction test>
FIG. 7 schematically shows the state of the test method. Hereinafter, the details of the test method will be described with reference to FIG.
Each of the above attractants was prepared as a test sample. Diluted so that the concentration of the attractant is a predetermined concentration (1%, 0.1%, etc.) was prepared as a test sample.
On the other hand, as a negative control sample, DMEM (Dulbecco's modified Eagle medium) “FBS (−), P / S (−)” was prepared.
As a positive control sample, a DMEM solution having a concentration of 20 ng / mL PDGF-BB (platelet-derived growth factor PEPRO TECH) was prepared.
First, mouse bone marrow stem cells (hereinafter also referred to as mMSC) are cultured and collected to confluence, suspended in 10% FBS / DMEM “P / S (−)” to 1 × 10 7 cells / ml, and cell suspension A liquid was prepared. FBS represents 10% fetal bovine serum, and P / S represents 100 unit penicillin and 0.1 mg / mL streptomycin. The symbol (-) indicates that no blending is performed.
Next, a Boyden chamber B (manufactured by Neuro Probe) having a plurality of independent wells, in which the well is partitioned into an upper well P and a lower well Q by a membrane M as shown in FIG. Prepared. One kind of each test sample was set so that a negative control sample and a positive control sample could be tested in the same Boyden chamber B, and 28 μL of each sample was applied to each lower well of the chamber B. As the membrane M of Boyden chamber B, the trade name “Polycarbonate Membranes” (pore size 8 μm, manufactured by Neuro Probe) was used.
Subsequently, 50 μL of the cell suspension was seeded in each upper well P, and cultured for 4 hours under conditions of 37 ° C. and 5% CO 2 (see (b) in FIG. 7).
After culturing for 4 hours, as shown in FIG. 7 (c), the unmigrated mMSC was removed with the attached filter wiper R, and only the mMSC that had moved to the lower side of the membrane M was subjected to Diff-Quick staining (Sysmex kit). Used).
Then, the stained image is digitized and loaded into a computer, and the image is converted to a white portion of the blue-stained portion so that the image is binarized into black and white. The measurement was performed using the function of editing software (trade name “Photoshop”). The mMSC attracting activity of each attractant was evaluated by comparing the brightness in the negative and positive control samples with the brightness in each test sample.
 細胞誘引試験の結果(輝度)を表1に示す。1%濃度、0.1%濃度などの所定濃度となるように誘引剤を希釈したサンプルを用いた結果のうち、輝度が最も高くなった結果を示す。また、同時に試験を行ったときの陽性対照及び陰性対照の結果も示す。表1から把握できるように、上記の各誘引剤は、骨髄幹細胞を誘引することができる。 The results (brightness) of the cell attraction test are shown in Table 1. Of the results obtained using the sample in which the attractant was diluted to a predetermined concentration such as 1% concentration or 0.1% concentration, the result of the highest luminance is shown. Moreover, the result of a positive control and a negative control when the test is performed simultaneously is also shown. As can be seen from Table 1, each of the above attractants can attract bone marrow stem cells.
Figure JPOXMLDOC01-appb-T000010
Figure JPOXMLDOC01-appb-T000010
<ヒトでの表皮改善作用の評価試験>
 7名の被験者で評価試験を行った。あらかじめ予備試験において、UV-B領域の紫外線を前腕内側部に照射して被験者ごとに最小紅斑量(MED)を決定した。上腕内側部の6箇所(1×1cm)に、1日1回、3日間、最小紅斑量(MED)の紫外線を照射して、人工的に色素斑を発生させた。
 この色素斑に1日2回、2ヶ月間、下記のいずれかを連続塗布し、色素斑消退度合いを評価した。
・骨髄幹細胞(MSC)誘引剤であるクスノハガシワ抽出物3質量%のみ
・クスノハガシワ抽出物3質量%(乾燥物換算0.006質量%)
 +分化誘導剤(ニーム葉抽出物 乾燥物換算0.011質量%、
        アッサム紅茶抽出物 乾燥物換算0.012質量%、
        ナス果実抽出物 乾燥物換算0.00505質量%)
  乾燥物換算でニーム葉抽出物:アッサム紅茶抽出物:ナス果実抽出物=
  2.2:2.4:1.0
 評価は、色差計により測定を行い、得られたマンセル値から、試料塗布部のΔL*(経時変化)を算出して行った。数値が大きいほど、色の消退量が大きい。結果を図6に示す。
<Evaluation test of human skin improvement>
An evaluation test was conducted with seven subjects. In a preliminary test, the minimum erythema amount (MED) was determined for each subject by irradiating the inner part of the forearm with ultraviolet rays in the UV-B region. Six spots (1 × 1 cm) on the inner side of the upper arm were irradiated with ultraviolet rays having a minimum erythema dose (MED) once a day for 3 days to artificially generate pigment spots.
One of the following was continuously applied to this pigment spot twice a day for two months, and the degree of pigment spot disappearance was evaluated.
・ Only 3% by mass of Kusunohagashi extract, which is an attractant for bone marrow stem cells (MSC) ・ 3% by mass of Kusunohagashi extract (0.006% by mass in terms of dry matter)
+ Differentiation-inducing agent (neem leaf extract, dry matter equivalent 0.011% by mass,
Assam black tea extract 0.012% by mass in terms of dry matter,
Eggplant fruit extract as dry matter 0.00505% by mass)
Neem leaf extract as dry matter: Assam black tea extract: Eggplant fruit extract =
2.2: 2.4: 1.0
The evaluation was performed by measuring with a color difference meter, and calculating ΔL * (change with time) of the sample application part from the obtained Munsell value. The larger the value, the greater the amount of color disappearance. The results are shown in FIG.
 本発明の分化誘導剤は、例えば、血流にのって体内を循環している骨髄幹細胞を表皮組織に誘引し、表皮組織において、誘引した骨髄幹細胞を表皮細胞へ分化させる目的で、好適に使用される。本発明の表皮改善剤、皮膚外用剤、及び、表皮改善方法は、上記のごとく表皮組織に骨髄幹細胞を誘引し、さらに、誘引された骨髄幹細胞を表皮細胞に分化させて、表皮機能を改善させる目的で、好適に使用される。例えば、本発明の表皮改善剤、皮膚外用剤は、表皮に塗布されることによって表皮に骨髄幹細胞を誘引して、誘引された骨髄幹細胞を表皮細胞に分化させて、肌の外観を改善させる目的で、好適に使用される。 The differentiation-inducing agent of the present invention is suitable for the purpose of, for example, attracting bone marrow stem cells circulating in the body in the bloodstream to the epidermis tissue and differentiating the induced bone marrow stem cells into epidermal cells in the epidermis tissue. used. The epidermis improving agent, external preparation for skin, and epidermal improvement method of the present invention, as described above, induces bone marrow stem cells to epidermal tissue, and further differentiates the induced bone marrow stem cells into epidermal cells to improve epidermal function. It is preferably used for the purpose. For example, the epidermis improving agent and the external preparation for skin of the present invention are applied to the epidermis to attract bone marrow stem cells to the epidermis, and the induced bone marrow stem cells are differentiated into epidermal cells to improve the appearance of the skin. And is preferably used.
 B:ボイデンチャンバー、 P:上部ウェル、 Q:下部ウェル、 M:メンブレン、 R:フィルターワイパー。 B: Boyden chamber, P: upper well, Q: lower well, M: membrane, R: filter wiper.

Claims (7)

  1.  ニーム葉抽出物と紅茶抽出物とを含む、骨髄幹細胞の分化誘導剤。 A bone marrow stem cell differentiation inducer comprising neem leaf extract and black tea extract.
  2.  ナス果実抽出物をさらに含む、請求項1に記載の分化誘導剤。 The differentiation inducer according to claim 1, further comprising eggplant fruit extract.
  3.  骨髄幹細胞の誘引剤と、ニーム葉抽出物と、紅茶抽出物とを含む、表皮改善剤。 An epidermis improving agent containing an attractant for bone marrow stem cells, neem leaf extract, and black tea extract.
  4.  ナス果実抽出物をさらに含む、請求項3に記載の表皮改善剤。 The epidermis improving agent according to claim 3, further comprising eggplant fruit extract.
  5.  骨髄幹細胞の誘引剤と、ニーム葉抽出物と、紅茶抽出物とを含む、皮膚外用剤。 An external preparation for skin containing an attractant for bone marrow stem cells, a neem leaf extract, and a tea extract.
  6.  ナス果実抽出物をさらに含む、請求項5に記載の皮膚外用剤。 The skin external preparation according to claim 5, further comprising eggplant fruit extract.
  7.  請求項3若しくは4に記載の表皮改善剤、又は、請求項5若しくは6に記載の皮膚外用剤を表皮に塗布することによって、骨髄幹細胞を表皮に誘引し、誘引した前記骨髄幹細胞を表皮細胞へ分化させることを備える、表皮改善方法。 By applying the epidermis improving agent according to claim 3 or 4 or the external preparation for skin according to claim 5 or 6 to the epidermis, the bone marrow stem cells are attracted to the epidermis, and the attracted bone marrow stem cells are converted into epidermal cells. A method for improving the epidermis, comprising differentiating.
PCT/JP2019/020506 2018-05-24 2019-05-23 Differentiation inducer of myeloid stem cells, agent for improving epidermis, skin external agent, and method for improving epidermis WO2019225707A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018099943A JP2019202966A (en) 2018-05-24 2018-05-24 Differentiation inducer for bone marrow stem cells, epidermis improving agent, skin external preparation, and epidermis improving method
JP2018-099943 2018-05-24

Publications (1)

Publication Number Publication Date
WO2019225707A1 true WO2019225707A1 (en) 2019-11-28

Family

ID=68615860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/020506 WO2019225707A1 (en) 2018-05-24 2019-05-23 Differentiation inducer of myeloid stem cells, agent for improving epidermis, skin external agent, and method for improving epidermis

Country Status (2)

Country Link
JP (1) JP2019202966A (en)
WO (1) WO2019225707A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008069074A (en) * 2006-09-12 2008-03-27 Kyoei Kagaku Kogyo Kk Cosmetic
KR20100025045A (en) * 2008-08-27 2010-03-09 (주)아모레퍼시픽 Composition for improving diabetes mellitus and for promoting the differentiation of human mesenchymal stem cell to adipocytic cells containing (-)catechin, (-)epicatechin gallate, (-)gallocatechin
JP2011251925A (en) * 2010-06-01 2011-12-15 Pias Arise Kk Mesenchymal stem cell inducer, and method for induction of mesenchymal stem cell
JP2013216646A (en) * 2012-03-12 2013-10-24 Pola Chemical Industries Inc Matrix metalloproteinase activity inhibitor and antimicrobial peptide production promoter
JP2014001192A (en) * 2012-06-21 2014-01-09 Pias Arise Kk Bone marrow stem cell inducer, and method for induction of bone marrow stem cell
WO2017188337A1 (en) * 2016-04-27 2017-11-02 キリン株式会社 Composition for improving skin texture which contains black tea extract as active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4562466B2 (en) * 2004-09-09 2010-10-13 一丸ファルコス株式会社 Neem extract production method and hypoallergenic cosmetic composition containing the same
JP2010143893A (en) * 2008-12-22 2010-07-01 Nikko Chemical Co Ltd ACTIVITY INHIBITOR OF SERINE PROTEASE HtrA1 AND/OR HtrA2
JP5900915B2 (en) * 2010-01-29 2016-04-06 共栄化学工業株式会社 Whitening cosmetics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008069074A (en) * 2006-09-12 2008-03-27 Kyoei Kagaku Kogyo Kk Cosmetic
KR20100025045A (en) * 2008-08-27 2010-03-09 (주)아모레퍼시픽 Composition for improving diabetes mellitus and for promoting the differentiation of human mesenchymal stem cell to adipocytic cells containing (-)catechin, (-)epicatechin gallate, (-)gallocatechin
JP2011251925A (en) * 2010-06-01 2011-12-15 Pias Arise Kk Mesenchymal stem cell inducer, and method for induction of mesenchymal stem cell
JP2013216646A (en) * 2012-03-12 2013-10-24 Pola Chemical Industries Inc Matrix metalloproteinase activity inhibitor and antimicrobial peptide production promoter
JP2014001192A (en) * 2012-06-21 2014-01-09 Pias Arise Kk Bone marrow stem cell inducer, and method for induction of bone marrow stem cell
WO2017188337A1 (en) * 2016-04-27 2017-11-02 キリン株式会社 Composition for improving skin texture which contains black tea extract as active ingredient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIN, GUORUI ET AL.: "Tissue engineered plant extracts as nanofibrous wound dressing", BIOMATERIALS, vol. 34, 2013, pages 724 - 734, XP055657136 *
KUGE, KATSUNORI. ET. AL.: "Search for activators that induce bone marrow-derived mesenchymal stem cells to differentiate into keratynocyte, Regenerative medicine", vol. 16, 2017, pages 449 *

Also Published As

Publication number Publication date
JP2019202966A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
JP5483661B2 (en) Slimming composition as a cosmetic containing an extract of biomass from the algae Neochloris oreo abundance
JP5572790B2 (en) Antioxidant, anti-inflammatory or anti-aging composition containing yew genus formation layer or pre-formation layer-derived plant stem cell line as an active ingredient
US9458429B2 (en) Mesenchymal stem cell attractant and method for attracting mesenchymal stem cell
KR101945862B1 (en) Anti-aging Composition Including Dendranthema zawadskii Extract, and Cosmetic Composition for young face by Anti-aging, Skin-lifting and Anti-wrinkle
KR101648148B1 (en) Cosmetic composition containing fermented graviola for improving anti-wrinkle and method of preparing the same
KR20180012647A (en) Cosmetic composition including extract of fermented ginseng using lactobacillus casei gfc1 and manufacturing method for the same
KR101394550B1 (en) Anti-bacterial or Anti-inflammatory Composition Comprising Extracts from Flower of Rosa hybrida as Active Ingredient
KR101815925B1 (en) Fermentated Composition of Barley Sprouts Dnhanced Policosanol and Method For Composition Thereof
WO2019225707A1 (en) Differentiation inducer of myeloid stem cells, agent for improving epidermis, skin external agent, and method for improving epidermis
JP2010202604A (en) Agent for normalization of skin indigenous microorganism, method for normalization of skin indigenous microorganism and dermatological external preparation or cosmetic using the same, and process for their productions
JP2019052109A (en) Muscle formation promoting composition
KR20130008823A (en) An improving method for antioxidant activity of extracts derived from natural herbal material and their application to cosmetic composition for the prevention of aging or medical composition for antioxidation and anti-inflammation
US20210338755A1 (en) Aqueous extract from cells of fitzroya cupressoides (alerce) with anti- aging and skin regeneration properties
JP6831049B2 (en) Method for producing a grunge fluorolic acid derivative exhibiting an NF-κB inhibitory effect
JP2014172859A (en) Cosmetic
CN117797055B (en) Compound essential oil for improving skin aging and skin care product composition containing compound essential oil
US20240099961A1 (en) Fermented extract of longoza seeds
JP6802537B1 (en) Dopaquinone derivatives exhibiting hemidesmosome activating action and methods for producing them
JP5820814B2 (en) Bone marrow stem cell attractant and bone marrow stem cell attracting method
US20220387295A1 (en) Novel microalgae having high loliolide productivity
KR102132514B1 (en) A cosmetic composition containing hot water extract or its ethyl acetate fraction from Sanguisorba officinalis having specific anti-microbial activity against acne-inducing bacterium
JP6600832B2 (en) Methylated flavonol derivatives exhibiting fat adsorption
KR20160094161A (en) Anti-dark circle composition comprising Scutellaria baicalensis extract
JP6010671B2 (en) Mesenchymal stem cell attractant
JP5231777B2 (en) Terpene derivative exhibiting apoptosis-inducing action and method for producing the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19807070

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19807070

Country of ref document: EP

Kind code of ref document: A1